Document:AXA/2025/FY/Earnings presentation: Difference between revisions
Appearance
Content deleted Content added
doc_archive: publish snjra2xp9r (original transcript) (.md link) |
doc_archive: publish snjra2xp9r (original transcript) |
||
| Line 11: | Line 11: | ||
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
| source_url = https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
| wide = yes |
| wide = yes |
||
| original_md = |
| original_md = <!-- ARCHIVE_MD_LINK_HERE --> |
||
| docling_file = |
| docling_file = <!-- ARCHIVE_DOCLING_LINK_HERE --> |
||
| article = AXA/2025/FY/Earnings presentation |
| article = AXA/2025/FY/Earnings presentation |
||
| doc_id = snjra2xp9r |
| doc_id = snjra2xp9r |
||
| Line 20: | Line 20: | ||
--- |
--- |
||
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
title: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
source_file: |
source_file: tmpk0bdd7ms.pdf |
||
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
source_url: https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf |
||
doc_type: slides |
doc_type: slides |
||
pages: 49 |
pages: 49 |
||
tables: |
tables: 55 |
||
converter: anchor_injection/1 |
converter: anchor_injection/1 |
||
tier: economic |
tier: economic |
||
parsed_at: '2026-07- |
parsed_at: '2026-07-22T09:01:31Z' |
||
scanned_pages: [] |
scanned_pages: [] |
||
--- |
--- |
||
| Line 33: | Line 33: | ||
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|1|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Full Year 2025 Earnings Presentation === |
=== Full Year 2025 Earnings Presentation February 26, 2026 === |
||
* February 26, 2026 |
|||
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|2|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 46: | Line 45: | ||
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|3|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Contents === |
|||
* 1. FY25 Highlights p.04 |
* 1. FY25 Highlights p.04 |
||
* Thomas Buberl, Group CEO |
* Thomas Buberl, Group CEO |
||
| Line 63: | Line 63: | ||
* +8% Underlying EPS vs. FY24 |
* +8% Underlying EPS vs. FY24 |
||
* 16% ROE FY25 |
* 16% ROE — FY25 |
||
* 224% Solvency II ratio FY25 |
* 224% Solvency II ratio — FY25 |
||
* Delivering value for shareholders +8% DPS{{fn ref|1|2=Based on the dividend proposed by AXA's Board of Directors on February 25, 2026 and subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.}} growth and €1.25bn annual share buy back{{fn ref|2|2=Following AXA's Board of Directors' approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
* Delivering value for shareholders +8% DPS{{fn ref|1|2=Based on the dividend proposed by AXA's Board of Directors on February 25, 2026 and subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.}} growth and €1.25bn annual share buy back{{fn ref|2|2=Following AXA's Board of Directors' approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
||
| Line 71: | Line 71: | ||
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
* Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026 |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Based on the dividend proposed by AXA's Board of Directors on February 25, 2026 and subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.}} |
{{fn note|1=1|2=Based on the dividend proposed by AXA's Board of Directors on February 25, 2026 and subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.}} |
||
{{fn note|1=2|2=Following AXA's Board of Directors' approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
{{fn note|1=2|2=Following AXA's Board of Directors' approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.}} |
||
</div> |
|||
{{pdf page|6|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|6|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 97: | Line 99: | ||
|} |
|} |
||
</div> |
</div> |
||
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
* High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%) |
||
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
* Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency |
||
| Line 102: | Line 105: | ||
* Consistent earnings growth while enhancing reserve prudence |
* Consistent earnings growth while enhancing reserve prudence |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change for Gross written premiums at constant scope and FX and for underlying earnings at constant FX.}} |
{{fn note|1=1|2=Change for Gross written premiums at constant scope and FX and for underlying earnings at constant FX.}} |
||
</div> |
|||
{{pdf page|7|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|7|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 108: | Line 113: | ||
==== Secular trends fueling demand across businesses ==== |
==== Secular trends fueling demand across businesses ==== |
||
* Protection gaps and emerging corporate risks |
|||
* Demographics driving demand for private retirement and healthcare |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t2" class="wikitable fintable" |
{| id="t2" class="wikitable fintable" |
||
|+ FY25 gross written premium split excluding AXA IM and holdings |
|+ FY25 gross written premium split (excluding AXA IM and holdings) |
||
|- |
|- |
||
! style="text-align:left" | Segment |
! style="text-align:left" | Segment |
||
| Line 123: | Line 132: | ||
|- |
|- |
||
| style="text-align:left" | Large & Specialty |
| style="text-align:left" | Large & Specialty |
||
| style="text-align:right" | 17% |
|||
|- |
|||
| style="text-align:left" | Retail |
|||
| style="text-align:right" | 17% |
| style="text-align:right" | 17% |
||
|- |
|- |
||
| style="text-align:left" | SME & Mid-market |
| style="text-align:left" | SME & Mid-market |
||
| style="text-align:right" | 16% |
| style="text-align:right" | 16% |
||
|- |
|||
| style="text-align:left" | Retail |
|||
| style="text-align:right" | 17% |
|||
|} |
|} |
||
</div> |
</div> |
||
<!-- furniture --> |
|||
* Protection gaps and emerging corporate risks |
|||
<!-- furniture --> |
|||
* Demographics driving demand for private retirement and healthcare |
|||
==== Our right to win ==== |
==== Our right to win ==== |
||
| Line 147: | Line 155: | ||
* Scale offering cost advantage |
* Scale offering cost advantage |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Pie chart represents FY25 gross written premium split excluding AXA IM and holdings.}} |
{{fn note|1=1|2=Pie chart represents FY25 gross written premium split excluding AXA IM and holdings.}} |
||
</div> |
|||
{{pdf page|8|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|8|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 163: | Line 173: | ||
{{pdf page|10|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|10|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
<!-- furniture --> |
|||
=== Strong delivery across our businesses === |
=== Strong delivery across our businesses === |
||
| Line 171: | Line 183: | ||
! style="text-align:right" | Gross written premiums |
! style="text-align:right" | Gross written premiums |
||
! style="text-align:right" | Underlying earnings |
! style="text-align:right" | Underlying earnings |
||
|- |
|||
| style="text-align:left" | France (27% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
|||
| style="text-align:right" | +6% to €31bn |
|||
| style="text-align:right" | +7% to €2.2bn |
|||
|- |
|||
| style="text-align:left" | Europe (38% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
|||
| style="text-align:right" | +6% to €43bn |
|||
| style="text-align:right" | +9% to €3.5bn |
|||
|- |
|||
| style="text-align:left" | AXA XL (17% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
|||
| style="text-align:right" | +4% to €19bn |
|||
| style="text-align:right" | +9% to €1.9bn |
|||
|- |
|||
| style="text-align:left" | Asia, Africa & EME-LATAM (18% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}}) |
|||
| style="text-align:right" | +13% to €20bn |
|||
| style="text-align:right" | +6% to €1.5bn |
|||
|} |
|} |
||
</div> |
</div> |
||
<tr><td>France (27% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}})</td><td>+6% to €31bn</td><td>+7% to €2.2bn</td></tr> |
|||
<tr><td>Europe (38% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}})</td><td>+6% to €43bn</td><td>+9% to €3.5bn</td></tr> |
|||
<tr><td>AXA XL (17% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}})</td><td>+4% to €19bn</td><td>+9% to €1.9bn</td></tr> |
|||
<tr><td>Asia, Africa & EME-LATAM (18% of total GWP{{fn ref|1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}})</td><td>+13% to €20bn</td><td>+6% to €1.5bn</td></tr> |
|||
</table> |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}} |
{{fn note|1=1|2=FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.}} |
||
</div> |
|||
{{pdf page|11|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|11|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 185: | Line 210: | ||
* €58bn GWP |
* €58bn GWP |
||
* GWP mix: Retail, SME & Mid-market, AXA XL{{fn ref|1|2=Includes AXA XL Re premiums of €2.6bn.}} (Large & Specialty) — shares not printed |
* GWP mix: Retail, SME & Mid-market, AXA XL{{fn ref|1|2=Includes AXA XL Re premiums of €2.6bn.}} (Large & Specialty) — shares not printed |
||
* Underlying earnings +9%{{fn ref|2|2=Change FY25 vs. FY24 at constant FX.}} to €5.9bn |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t4" class="wikitable" |
{| id="t4" class="wikitable" |
||
|+ 2025 and Beyond |
|+ 2025 and Beyond 2025 outlook |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 205: | Line 233: | ||
</div> |
</div> |
||
* Continued progress on efficiency |
|||
* Underlying earnings +9%{{fn ref|2|2=Change FY25 vs. FY24 at constant FX.}} to €5.9bn |
|||
* |
* Higher investment income |
||
* Data & AI to further enhance customer experience & technical excellence |
* Data & AI to further enhance customer experience & technical excellence |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Includes AXA XL Re premiums of €2.6bn.}} |
{{fn note|1=1|2=Includes AXA XL Re premiums of €2.6bn.}} |
||
{{fn note|1=2|2=Change FY25 vs. FY24 at constant FX.}} |
{{fn note|1=2|2=Change FY25 vs. FY24 at constant FX.}} |
||
</div> |
|||
{{pdf page|12|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|12|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 217: | Line 247: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t5" class="wikitable" |
{| id="t5" class="wikitable" |
||
|+ |
|+ GWP |
||
|- |
|- |
||
| style="text-align:left" | Short-term |
| style="text-align:left" | Short-term |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|||
| style="text-align:left" | Long-term |
|||
| style="text-align:right" | |
|||
|- |
|||
| style="text-align:left" | Total GWP |
|||
| style="text-align:right" | €57bn |
|||
|} |
|} |
||
</div> |
</div> |
||
* Underlying earnings +7%{{fn ref|1|2=1. Change FY25 vs. FY24 at constant FX.}} to €3.5bn |
|||
==== 2025 Beyond 2025 ==== |
==== 2025 Beyond 2025 ==== |
||
* Long-term business |
* Long-term business |
||
* |
* Accelerating net flows in Savings at attractive margins |
||
* |
* Capturing savings & retirement opportunity, sourcing best asset management products for our customers |
||
* Short-term business |
* Short-term business |
||
* |
* Growing technical results while absorbing Mexico VAT impact |
||
* |
* Capitalizing on demand for health & protection while further improving our margins |
||
* Underlying earnings +7%{{fn ref|1|2=Change FY25 vs. FY24 at constant FX.}} to €3.5bn |
|||
* Focus on cost reduction |
* Focus on cost reduction |
||
* Increasing penetration of Protection riders in Savings offerings |
* Increasing penetration of Protection riders in Savings offerings |
||
* Leveraging AI to reduce claims leakage & improve customer outcomes in Health |
* Leveraging AI to reduce claims leakage & improve customer outcomes in Health |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change FY25 vs. FY24 at constant FX.}} |
|||
{{fn note|1=1|2=1. Change FY25 vs. FY24 at constant FX.}} |
|||
</div> |
|||
{{pdf page|13|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|13|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 254: | Line 293: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t6" class="wikitable fintable" |
{| id="t6" class="wikitable fintable" |
||
|+ GWP & Other Revenues |
|+ GWP & Other Revenues (In Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Segment |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 264: | Line 303: | ||
|- |
|- |
||
| style="text-align:left" | Commercial lines |
| style="text-align:left" | Commercial lines |
||
| |
| style="text-align:right" | |
||
| style="text-align:right" | 35.8 |
| style="text-align:right" | 35.8 |
||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
| Line 271: | Line 310: | ||
|- |
|- |
||
| style="text-align:left" | AXA XL Reinsurance |
| style="text-align:left" | AXA XL Reinsurance |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 2.6 |
| style="text-align:right" | 2.6 |
||
| style="text-align:right" | +8% |
| style="text-align:right" | +8% |
||
| Line 277: | Line 317: | ||
|- |
|- |
||
| style="text-align:left" | Retail lines |
| style="text-align:left" | Retail lines |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 19.7 |
| style="text-align:right" | 19.7 |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7% |
||
| Line 291: | Line 332: | ||
</div> |
</div> |
||
* Continued pricing momentum and volume growth in Mid-market and SME |
* Continued pricing momentum and volume growth in Mid-market and SME |
||
* Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance |
|||
* Growth supported by alternative capital |
* Growth supported by alternative capital |
||
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
* Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25) |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Price effect.}} |
{{fn note|1=1|2=Price effect.}} |
||
{{fn note|1=2|2=Includes exposure adjustments and mix & other effects.}} |
{{fn note|1=2|2=Includes exposure adjustments and mix & other effects.}} |
||
</div> |
|||
{{pdf page|15|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|15|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 311: | Line 355: | ||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Combined ratio |
| style="text-align:left" | Combined ratio |
||
| style="text-align:right" | 91.0% |
| style="text-align:right" | 91.0% |
||
| style="text-align:right" | 90.6% |
| style="text-align:right" | 90.6% |
||
| Line 353: | Line 397: | ||
=== P&C – Earnings growth from higher underwriting and financial result === |
=== P&C – Earnings growth from higher underwriting and financial result === |
||
In Euro million |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 365: | Line 409: | ||
| style="text-align:right" | 5,510 |
| style="text-align:right" | 5,510 |
||
|- |
|- |
||
| style="text-align:left" | Volume growth |
| style="text-align:left" | Volume growth ( Underwriting result{{fn ref|1|2=Underwriting result includes expenses.}}) |
||
| style="text-align:right" | +292 |
| style="text-align:right" | +292 |
||
|- |
|- |
||
| Line 371: | Line 415: | ||
| style="text-align:right" | +189 |
| style="text-align:right" | +189 |
||
|- |
|- |
||
| style="text-align:left" | Investment income |
| style="text-align:left" | Investment income ( Financial result) |
||
| style="text-align:right" | +435 |
| style="text-align:right" | +435 |
||
|- |
|- |
||
| style="text-align:left" | Insurance |
| style="text-align:left" | Insurance finance expenses |
||
| style="text-align:right" | -235 |
| style="text-align:right" | -235 |
||
|- |
|- |
||
| Line 389: | Line 433: | ||
* +9% |
* +9% |
||
* Underwriting result{{fn ref|1|2=Change at constant FX. 1. Underwriting result includes expenses.}} |
|||
* Financial result |
|||
* Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence |
* Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence |
||
| Line 402: | Line 442: | ||
* Unfavorable forex impact notably due to USD depreciation vs. EUR |
* Unfavorable forex impact notably due to USD depreciation vs. EUR |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change at constant FX. 1. Underwriting result includes expenses.}} |
|||
{{fn note|1=1|2=Underwriting result includes expenses.}} |
|||
</div> |
|||
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|17|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Life & Health – Strong growth in premiums, positive net flows === |
=== Life & Health – Strong growth in premiums, positive net flows === |
||
* In Euro billion |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 415: | Line 459: | ||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Growth |
! class="col-s" style="text-align:right" | Growth |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 34.5 |
|||
| style="text-align:right" | 37.5 |
|||
| style="text-align:right" | +9% |
|||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| Line 435: | Line 484: | ||
| style="text-align:right" | 1.9 |
| style="text-align:right" | 1.9 |
||
| style="text-align:right" | -7% |
| style="text-align:right" | -7% |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 34.5 |
|||
| style="text-align:right" | 37.5 |
|||
| style="text-align:right" | +9% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 451: | Line 495: | ||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-s" style="text-align:right" | Growth |
! class="col-s" style="text-align:right" | Growth |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 17.5 |
|||
| style="text-align:right" | 19.0 |
|||
| style="text-align:right" | +5% |
|||
|- |
|- |
||
| style="text-align:left" | Individual |
| style="text-align:left" | Individual |
||
| Line 461: | Line 510: | ||
| style="text-align:right" | 8.5 |
| style="text-align:right" | 8.5 |
||
| style="text-align:right" | +4% |
| style="text-align:right" | +4% |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 17.5 |
|||
| style="text-align:right" | 19.0 |
|||
| style="text-align:right" | +5% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 474: | Line 518: | ||
|- |
|- |
||
! style="text-align:left" | Segment |
! style="text-align:left" | Segment |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Net flows |
||
|- |
|- |
||
| style="text-align:left" | Protection |
| style="text-align:left" | Protection |
||
| Line 493: | Line 537: | ||
</div> |
</div> |
||
o/w FY25 Employee Benefits{{fn ref|1|2= |
* o/w FY25 Employee Benefits{{fn ref|1|2=Including both short-term and long-term Employee Benefits GWP and other revenues.}} |
||
Euro 12.9 billion (+4% vs. FY24) |
* Euro 12.9 billion (+4% vs. FY24) Change at constant scope and FX. |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change at constant scope and FX. Including both short-term and long-term Employee Benefits GWP and other revenues.}} |
|||
{{fn note|1=1|2=Including both short-term and long-term Employee Benefits GWP and other revenues.}} |
|||
</div> |
|||
{{pdf page|18|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|18|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
=== Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting === |
||
* In Euro billion |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
| Line 512: | Line 556: | ||
|- |
|- |
||
| style="text-align:left" | Protection & Health |
| style="text-align:left" | Protection & Health |
||
| |
| style="text-align:right" | |
||
| style="text-align:right" | 31.4 |
| style="text-align:right" | 31.4 |
||
|- |
|- |
||
| style="text-align:left" | Unit-Linked |
| style="text-align:left" | Unit-Linked |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 8.5 |
| style="text-align:right" | 8.5 |
||
|- |
|- |
||
| style="text-align:left" | Capital-light G/A |
| style="text-align:left" | Capital-light G/A |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 7.8 |
| style="text-align:right" | 7.8 |
||
|- |
|- |
||
| style="text-align:left" | Traditional G/A |
| style="text-align:left" | Traditional G/A |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 1.7 |
| style="text-align:right" | 1.7 |
||
|- |
|- |
||
| Line 529: | Line 576: | ||
|- |
|- |
||
| style="text-align:left" | Change |
| style="text-align:left" | Change |
||
| style="text-align:right" | |
| colspan="2" style="text-align:right" | -2% |
||
| style="text-align:right" | -2% |
|||
|- |
|- |
||
| style="text-align:left" | Protection & Health change |
| style="text-align:left" | Protection & Health change |
||
| style="text-align:right" | |
| colspan="2" style="text-align:right" | -4% |
||
| style="text-align:right" | -4% |
|||
|- |
|- |
||
| style="text-align:left" | Unit-Linked change |
| style="text-align:left" | Unit-Linked change |
||
| style="text-align:right" | |
| colspan="2" style="text-align:right" | +18% |
||
| style="text-align:right" | +18% |
|||
|- |
|- |
||
| style="text-align:left" | Capital-light G/A change |
| style="text-align:left" | Capital-light G/A change |
||
| style="text-align:right" | |
| colspan="2" style="text-align:right" | -10% |
||
| style="text-align:right" | -10% |
|||
|- |
|- |
||
| style="text-align:left" | Traditional G/A change |
| style="text-align:left" | Traditional G/A change |
||
| style="text-align:right" | |
| colspan="2" style="text-align:right" | -10% |
||
| style="text-align:right" | -10% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 554: | Line 596: | ||
|+ NB CSM (pre-tax) |
|+ NB CSM (pre-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | FY24 |
||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 2.2 |
||
| style="text-align:right" | 2.2 |
|||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
|- |
|- |
||
| style="text-align:left" | |
| colspan="2" style="text-align:left" | +3% |
||
| style="text-align:right" | |
|||
| style="text-align:right" | +3% |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 572: | Line 610: | ||
|+ NBV (post-tax) |
|+ NBV (post-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | FY24 |
||
! class="col-s" style="text-align:right" | FY24 |
|||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 2.3 |
||
| style="text-align:right" | 2.3 |
|||
| style="text-align:right" | 2.2 |
| style="text-align:right" | 2.2 |
||
|- |
|- |
||
| style="text-align:left" | |
| colspan="2" style="text-align:left" | stable |
||
| style="text-align:right" | |
|||
| style="text-align:right" | stable |
|||
|- |
|- |
||
| style="text-align:left" | NBV margin |
| style="text-align:left" | NBV margin 4.4% |
||
| style="text-align:right" | 4.4% |
|||
| style="text-align:right" | 4.5% |
| style="text-align:right" | 4.5% |
||
|} |
|} |
||
| Line 596: | Line 629: | ||
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France |
* NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France |
||
* Change at constant scope and FX. |
|||
{{pdf page|19|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|19|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 617: | Line 650: | ||
! style="text-align:right" | Affiliates, FX & other |
! style="text-align:right" | Affiliates, FX & other |
||
! style="text-align:right" | FY25 |
! style="text-align:right" | FY25 |
||
|- |
|||
| style="text-align:left" | 33.6 |
|||
| style="text-align:right" | +2.2 |
|||
| style="text-align:left" | +1.3 |
|||
| style="text-align:right" | -3.0 |
|||
| style="text-align:right" | +0.6 |
|||
| style="text-align:right" | -0.3 |
|||
| style="text-align:right" | -1.4 |
|||
| style="text-align:right" | 33.0 |
|||
|- |
|||
| colspan="8" style="text-align:left" | Normalized CSM growth +2% |
|||
|} |
|} |
||
</div> |
</div> |
||
<tr><td>33.6</td><td>+2.2</td><td>+1.3</td><td>-3.0</td><td>+0.6</td><td>-0.3</td><td>-1.4</td><td>33.0</td></tr> |
|||
<tr><td>o/w Life: 25.8</td><td></td><td></td><td></td><td></td><td></td><td></td><td>25.4</td></tr> |
|||
<tr><td>o/w Health: 7.7</td><td></td><td></td><td></td><td></td><td></td><td></td><td>7.6</td></tr> |
|||
</table> |
|||
* o/w Life: 25.8 (FY24) → 25.4 (FY25) |
|||
* Normalized CSM growth +2% |
|||
* o/w Health: 7.7 (FY24) → 7.6 (FY25) |
|||
* Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates |
* Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates |
||
| Line 634: | Line 676: | ||
* FX impact mainly from JPY and HKD depreciation |
* FX impact mainly from JPY and HKD depreciation |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change at constant scope and FX.}} |
{{fn note|1=1|2=Change at constant scope and FX.}} |
||
</div> |
|||
{{pdf page|20|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|20|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Life & Health – Strong momentum in both short-term and long-term business === |
=== Life & Health – Strong momentum in both short-term and long-term business === |
||
In Euro million |
|||
==== Underlying Earnings ==== |
==== Underlying Earnings +7% ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t16" class="wikitable fintable" |
{| id="t16" class="wikitable fintable" |
||
|+ Underlying Earnings (In Euro million) |
|+ Underlying Earnings waterfall (In Euro million) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Step |
||
! class="col-s" style="text-align:right" | |
! class="col-s" style="text-align:right" | Value |
||
|- |
|||
! style="text-align:left" | Short-term technical margin |
|||
| style="text-align:left" | FY24 |
|||
| style="text-align:right" | 3,323 |
|||
! class="col-s" style="text-align:right" | Tax, FX and others |
|||
! class="col-s" style="text-align:right" | FY25 |
|||
|- |
|- |
||
| style="text-align:left" | Short-term technical margin |
| style="text-align:left" | Short-term technical margin |
||
| style="text-align:right" | |
| style="text-align:right" | +60 |
||
| style="text-align:left" | +60 |
|||
| style="text-align:left" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | 479 |
|||
|- |
|- |
||
| style="text-align:left" | Long-term result incl. CSM release |
| style="text-align:left" | Long-term result incl. CSM release |
||
| style="text-align:right" | |
| style="text-align:right" | +156 |
||
| style="text-align:left" | |
|||
| style="text-align:left" | +156 |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | 2,804 |
|||
|- |
|- |
||
| style="text-align:left" | Financial result |
| style="text-align:left" | Financial result |
||
| style="text-align:right" | 975 |
|||
| style="text-align:left" | |
|||
| style="text-align:left" | |
|||
| style="text-align:right" | -11 |
| style="text-align:right" | -11 |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 946 |
|||
|- |
|- |
||
| style="text-align:left" | Tax |
| style="text-align:left" | Tax, FX and others |
||
| style="text-align:right" | -748 |
|||
| style="text-align:left" | |
|||
| style="text-align:left" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | -27 |
| style="text-align:right" | -27 |
||
| style="text-align:right" | -728 |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | FY25 |
||
| style="text-align:right" | 3,323 |
|||
| style="text-align:left" | |
|||
| style="text-align:left" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | 3,501 |
| style="text-align:right" | 3,501 |
||
|} |
|} |
||
</div> |
</div> |
||
* +7% Underlying Earnings |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t17" class="wikitable fintable" |
{| id="t17" class="wikitable fintable" |
||
|+ FY24 vs FY25 Underlying Earnings breakdown (In Euro million) |
|||
|+ in billions |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col-m" style="text-align:right" | Change at constant FX |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Short-term technical margin |
||
| style="text-align:right" | |
| style="text-align:right" | 415 |
||
| style="text-align:right" | |
| style="text-align:right" | 479 |
||
| style="text-align:right" | +4% vs. FY24 |
|||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Long-term result incl. CSM release |
||
| style="text-align:right" | |
| style="text-align:right" | 2,680 |
||
| style="text-align:right" | |
| style="text-align:right" | 2,804 |
||
|- |
|||
| style="text-align:right" | +17% vs. FY24 |
|||
| style="text-align:left" | Financial result |
|||
| style="text-align:right" | 975 |
|||
| style="text-align:right" | 946 |
|||
|- |
|||
| style="text-align:left" | Tax & others |
|||
| style="text-align:right" | -748 |
|||
| style="text-align:right" | -728 |
|||
|} |
|} |
||
</div> |
</div> |
||
* o/w Life: 2.6 → 2.7 in billions — +4% vs. FY24 |
|||
* o/w Health: 0.7 → 0.8 in billions — +17% vs. FY24 |
|||
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn) |
* Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn) |
||
| Line 724: | Line 747: | ||
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins |
* Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change at constant FX.}} |
{{fn note|1=1|2=Change at constant FX.}} |
||
</div> |
|||
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|21|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 793: | Line 818: | ||
==== Underlying earnings per share ==== |
==== Underlying earnings per share ==== |
||
In Euro |
In Euro |
||
| Line 813: | Line 837: | ||
* +3% from capital management |
* +3% from capital management |
||
* -2% from forex |
* -2% from forex |
||
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback |
* including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback |
||
<!-- furniture --> |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Change at constant FX for underlying earnings and net income. Change on reported basis for underlying earnings per share.}} |
{{fn note|1=1|2=Change at constant FX for underlying earnings and net income. Change on reported basis for underlying earnings per share.}} |
||
</div> |
|||
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|22|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Shareholders' Equity === |
=== Shareholders' Equity === |
||
* In Euro billion |
|||
==== Shareholders' equity{{fn ref|1|2=Shareholders' equity Group share. Full Year 2025 Earnings}} ==== |
==== Shareholders' equity{{fn ref|1|2=Shareholders' equity Group share. Full Year 2025 Earnings}} ==== |
||
| Line 825: | Line 854: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t20" class="wikitable fintable" |
{| id="t20" class="wikitable fintable" |
||
|+ Shareholders' equity |
|+ Shareholders' equity |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 831: | Line 860: | ||
! class="col-s" style="text-align:right" | HY25 |
! class="col-s" style="text-align:right" | HY25 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 49.9 |
|||
| style="text-align:right" | 45.5 |
|||
| style="text-align:right" | 47.2 |
|||
|- |
|- |
||
| style="text-align:left" | SHE (excl. OCI) |
| style="text-align:left" | SHE (excl. OCI) |
||
| Line 846: | Line 870: | ||
| style="text-align:right" | -7.2 |
| style="text-align:right" | -7.2 |
||
| style="text-align:right" | -6.8 |
| style="text-align:right" | -6.8 |
||
|- |
|||
| style="text-align:left" | Shareholders' Equity |
|||
| style="text-align:right" | 49.9 |
|||
| style="text-align:right" | 45.5 |
|||
| style="text-align:right" | 47.2 |
|||
|- |
|- |
||
| style="text-align:left" | SHE (excl. OCI & undated subordinated debt) |
| style="text-align:left" | SHE (excl. OCI & undated subordinated debt) |
||
| Line 913: | Line 942: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Shareholders' equity Group share. Full Year 2025 Earnings}} |
{{fn note|1=1|2=Shareholders' equity Group share. Full Year 2025 Earnings}} |
||
</div> |
|||
{{pdf page|23|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|23|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 928: | Line 959: | ||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col- |
! class="col-m" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Proceeds related to in-force treaties{{fn ref|2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
| style="text-align:left" | Proceeds related to in-force treaties{{fn ref|2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
||
| Line 934: | Line 965: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|- |
||
| style="text-align:left" | Ordinary |
| style="text-align:left" | Ordinary remittance |
||
| style="text-align:right" | 7.1 |
| style="text-align:right" | 7.1 |
||
| style="text-align:right" | 7.5 |
| style="text-align:right" | 7.5 |
||
| Line 940: | Line 971: | ||
| style="text-align:left" | Total |
| style="text-align:left" | Total |
||
| style="text-align:right" | 7.7 |
| style="text-align:right" | 7.7 |
||
| style="text-align:right" | 7.5 |
| style="text-align:right" | <strong>7.5</strong> |
||
|- |
|- |
||
| style="text-align:left" | Remittance ratio{{fn ref|1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
| style="text-align:left" | Remittance ratio{{fn ref|1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
||
| Line 980: | Line 1,011: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
{{fn note|1=1|2=Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.}} |
||
{{fn note|1=2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
{{fn note|1=2|2=€0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.}} |
||
</div> |
|||
{{pdf page|24|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|24|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Solvency II at 224% === |
=== Solvency II at 224% === |
||
In Euro billion Foreseeable dividends: €-4.8bn Provision for annual share buyback for 2026: €-1.25bn |
* In Euro billion Foreseeable dividends: €-4.8bn Provision for annual share buyback for 2026: €-1.25bn |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id="t24" class="wikitable" |
{| id="t24" class="wikitable fintable" |
||
|+ Eligible Own Funds (EOF) |
|+ Eligible Own Funds (EOF) / Solvency Capital Requirement (SCR) / Solvency II ratio bridge FY24–FY25 |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! style="text-align: |
! class="col-s" style="text-align:right" | FY24 |
||
! style="text-align: |
! class="col-s" style="text-align:right" | Regulatory & model changes |
||
! style="text-align:right" | |
! class="col-s" style="text-align:right" | Normalized capital generation |
||
! style="text-align:right" | |
! class="col-s" style="text-align:right" | Operating variance |
||
! class="col-s" style="text-align:right" | Economic variance & FX |
|||
! style="text-align:left" | Dividend & annual share buyback |
! style="text-align:left" | Dividend & annual share buyback |
||
! style="text-align: |
! class="col-s" style="text-align:right" | Management actions, debt & other |
||
! style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|} |
|||
</div> |
|||
<tr><td> 55.9</td><td> +0.2</td><td> +8.8</td><td> -0.4</td><td> -2.1</td><td> -6.0 -0.1</td><td></td><td>56.4</td></tr> |
|||
</table> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t25" class="wikitable" |
|||
|+ Solvency II ratio |
|||
|- |
|- |
||
| style="text-align:left" | Eligible Own Funds (EOF) |
|||
| style="text-align:right" | 55.9 |
|||
| style="text-align:right" | +0.2 |
|||
| style="text-align:right" | +8.8 |
|||
| style="text-align:right" | -0.4 |
|||
| style="text-align:right" | -2.1 |
|||
| style="text-align:left" | -6.0 / -0.1 |
|||
| style="text-align:right" | |
|||
| style="text-align:right" | 56.4 |
|||
|} |
|||
|- |
|||
</div> |
|||
| style="text-align:left" | Solvency II ratio |
|||
| style="text-align:right" | 216% |
|||
<tr><td>216%</td><td>+0pt</td><td>+28pts</td><td>-1pt</td><td>+4pts</td><td>-24pts</td><td>+2pts</td><td>224%</td></tr> |
|||
| style="text-align:right" | +0pt |
|||
</table> |
|||
| style="text-align:right" | +28pts |
|||
| style="text-align:right" | -1pt |
|||
| style="text-align:right" | +4pts |
|||
{| id="t26" class="wikitable" |
|||
| style="text-align:left" | -24pts |
|||
|+ Solvency Capital Requirement (SCR) |
|||
| style="text-align:right" | +2pts |
|||
| style="text-align:right" | 224% |
|||
|- |
|- |
||
| style="text-align:left" | Solvency Capital Requirement (SCR) |
|||
| style="text-align:right" | 25.9 |
|||
| style="text-align:right" | 0.0 |
|||
| style="text-align:right" | +0.6 |
|||
| style="text-align:right" | 0.0 |
|||
| style="text-align:right" | -1.2 |
|||
| style="text-align:left" | 0.0 |
|||
| style="text-align:right" | -0.2 |
|||
| style="text-align:right" | 25.2 |
|||
|} |
|} |
||
</div> |
</div> |
||
<tr><td>25.9</td><td>0.0</td><td>+0.6</td><td>0.0</td><td>-1.2</td><td>0.0</td><td>-0.2</td><td>25.2</td></tr> |
|||
</table> |
|||
==== Key sensitivities ==== |
==== Key sensitivities ==== |
||
* Ratio as of December 31, 2025: 224% |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t25" class="wikitable fintable" |
||
|+ Key sensitivities |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Sensitivity |
||
! class="col-s" style="text-align:right" | Impact |
! class="col-s" style="text-align:right" | Impact |
||
|- |
|||
| style="text-align:left" | Ratio as of December 31, 2025 |
|||
| style="text-align:right" | 224% |
|||
|- |
|- |
||
| style="text-align:left" | Interest rate +50bps |
| style="text-align:left" | Interest rate +50bps |
||
| Line 1,063: | Line 1,088: | ||
|- |
|- |
||
| style="text-align:left" | Euro Sovereign spreads +50bps{{fn ref|1|2=Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).}} |
| style="text-align:left" | Euro Sovereign spreads +50bps{{fn ref|1|2=Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).}} |
||
| style="text-align:right" | - |
| style="text-align:right" | -7 pts |
||
|- |
|- |
||
| style="text-align:left" | Credit migration{{fn ref|2|2=Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).}} |
| style="text-align:left" | Credit migration{{fn ref|2|2=Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).}} |
||
| style="text-align:right" | |
| style="text-align:right" | -4 pts |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity (excl. PE & Infra) +25% |
| style="text-align:left" | Listed Equity (excl. PE & Infra) +25% |
||
| style="text-align:right" | - |
| style="text-align:right" | -1 pt |
||
|- |
|- |
||
| style="text-align:left" | Listed Equity (excl. PE & Infra) -25% |
| style="text-align:left" | Listed Equity (excl. PE & Infra) -25% |
||
| style="text-align:right" | |
| style="text-align:right" | +2 pts |
||
|- |
|- |
||
| style="text-align:left" | PE & Infra +25% |
| style="text-align:left" | PE & Infra +25% |
||
| Line 1,085: | Line 1,110: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).}} |
{{fn note|1=1|2=Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).}} |
||
{{fn note|1=2|2=Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).}} |
{{fn note|1=2|2=Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).}} |
||
</div> |
|||
{{pdf page|25|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|25|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Solvency II – impact of the end of grandfathering period and Solvency II revision === |
=== Solvency II – impact of the end of grandfathering period and Solvency II revision === |
||
* Ratio as of 31/12/2025: 224% |
|||
<div style="overflow-x:auto"> |
|||
* Impact of the end of grandfathering period on January 1, 2026: -10pts to 215% |
|||
{| id="t28" class="wikitable" |
|||
* Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026 |
|||
|- |
|||
* Impact of Solvency II revision to come into effect in 1Q27: +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
|||
| style="text-align:left" | Ratio as of 31/12/2025 |
|||
* No change expected in organic capital generation |
|||
| style="text-align:right" | 224% |
|||
* Additional capital flexibility |
|||
| style="text-align:left" | |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
|- |
|||
{{fn note|1=1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
|||
| style="text-align:left" | Impact of the end of grandfathering period on January 1, 2026 |
|||
| style="text-align:right" | -10pts to 215% |
|||
| style="text-align:left" | Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026 |
|||
|- |
|||
| style="text-align:left" | Impact of Solvency II revision to come into effect in 1Q27 |
|||
| style="text-align:right" | +17pts{{fn ref|1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
|||
| style="text-align:left" | |
|||
|} |
|||
</div> |
</div> |
||
No change expected in organic capital generation<br/> |
|||
Additional capital flexibility |
|||
</td> |
|||
</tr> |
|||
</table> |
|||
{{fn note|1=1|2=Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.}} |
|||
{{pdf page|26|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|26|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
== Conclusion == |
== Conclusion == |
||
* Thomas Buberl, Group CEO |
* Thomas Buberl, Group CEO |
||
{{pdf page|27|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|27|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Conclusion === |
=== Conclusion === |
||
* Record results, at the top end of the target range while enhancing reserve prudence |
* Record results, at the top end of the target range while enhancing reserve prudence |
||
* All businesses in excellent shape, delivering strong growth and profitability |
* All businesses in excellent shape, delivering strong growth and profitability |
||
| Line 1,127: | Line 1,141: | ||
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|28|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
== Q&A == |
=== Q&A === |
||
February 26, 2026 |
February 26, 2026 |
||
* <!-- furniture --> |
|||
* <!-- furniture --> |
|||
* <!-- furniture --> |
|||
* <!-- furniture --> |
|||
* <!-- furniture --> |
|||
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|29|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,140: | Line 1,149: | ||
==== Meet our management ==== |
==== Meet our management ==== |
||
* March |
* March | Roadshows | Europe and US |
||
* May 5 |
* May 5 | 1Q25 Activity Indicators | Paris |
||
* June 2 |
* June 2 | BNP Paribas Exane CEO Conference | Paris |
||
* June 2-4 |
* June 2-4 | Goldman Sachs European Financials Conference | Zurich |
||
* July 31 |
* July 31 | HY26 Earnings Release | Paris |
||
* September 21 |
* September 21 | AXA Investor Day | London |
||
==== Contact us ==== |
==== Contact us ==== |
||
| Line 1,159: | Line 1,168: | ||
{{pdf page|31|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|31|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Contents === |
|||
* 1. Debt and Invested Assets p.31 |
* 1. Debt and Invested Assets p.31 |
||
* 2. Additional P&C disclosures p.36 |
* 2. Additional P&C disclosures p.36 |
||
| Line 1,168: | Line 1,178: | ||
* In Euro billion |
* In Euro billion |
||
==== Gross financial debt{{fn ref|1,2|2=1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} ==== |
==== Gross financial debt{{fn ref|1,2|2=1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} Contractual maturity breakdown ==== |
||
* Debt gearing 20.6% 22.3% |
* Debt gearing 20.6% 22.3% |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t26" class="wikitable fintable" |
||
|+ Gross financial debt (In Euro billion) |
|+ Gross financial debt (In Euro billion) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col- |
! class="col-m" style="text-align:right" | FY24 |
||
! class="col- |
! class="col-m" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-m" style="text-align:right" | Jan 1st 2026 |
||
|- |
|||
| style="text-align:left" | Total |
|||
| style="text-align:right" | 19.2 |
|||
| style="text-align:right" | 20.3 |
|||
| style="text-align:right" | 20.3 |
|||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| Line 1,200: | Line 1,205: | ||
| style="text-align:right" | 3.5 |
| style="text-align:right" | 3.5 |
||
| style="text-align:right" | 5.8 |
| style="text-align:right" | 5.8 |
||
|- |
|||
| style="text-align:left" | <strong>Total</strong> |
|||
| style="text-align:right" | <strong>19.2</strong> |
|||
| style="text-align:right" | <strong>20.3</strong> |
|||
| style="text-align:right" | <strong>20.3</strong> |
|||
|} |
|} |
||
</div> |
</div> |
||
* End of the grandfathering period |
* Jan 1st 2026: End of the grandfathering period |
||
* o/w €0.4bn redeemed in Jan 2026 |
* o/w €0.4bn redeemed in Jan 2026 |
||
* Legend: Tier 1, Tier 2, Senior debt |
|||
==== Contractual maturity breakdown ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t27" class="wikitable fintable" |
||
|+ Contractual maturity breakdown (In Euro billion) |
|+ Contractual maturity breakdown (In Euro billion) |
||
|- |
|- |
||
| Line 1,230: | Line 1,240: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | 0.9 |
||
| style="text-align:right" | 1.5 |
| style="text-align:right" | 1.5 |
||
| style="text-align:right" | 0.5 |
| style="text-align:right" | 0.5 |
||
| Line 1,240: | Line 1,250: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 0.5 |
| style="text-align:right" | 0.5 |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 0.7 |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | 10.8 |
| style="text-align:right" | 10.8 |
||
| style="text-align:right" | |
| style="text-align:right" | 4.6 |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|- |
||
| Line 1,254: | Line 1,264: | ||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
|} |
|} |
||
</div> |
</div> |
||
==== o/w Grandfathered debt (Contractual maturity breakdown) ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t28" class="wikitable fintable" |
||
|+ Contractual maturity breakdown – o/w Grandfathered debt |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,303: | Line 1,312: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t29" class="wikitable fintable" |
||
|+ Economic maturity breakdown (In Euro billion) |
|+ Economic maturity breakdown (In Euro billion) |
||
|- |
|- |
||
| Line 1,332: | Line 1,341: | ||
| style="text-align:right" | 0.1 |
| style="text-align:right" | 0.1 |
||
| style="text-align:right" | 2.4 |
| style="text-align:right" | 2.4 |
||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | 0.5 |
| style="text-align:right" | 0.5 |
||
| style="text-align:right" | 2.0 |
| style="text-align:right" | 2.0 |
||
| style="text-align:right" | 0.4 |
|||
| style="text-align:right" | 6.4 |
| style="text-align:right" | 6.4 |
||
| style="text-align:right" | |
| style="text-align:right" | 0.7 |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
|- |
|- |
||
| style="text-align:left" | Tier 1 |
| style="text-align:left" | Tier 1 |
||
| style="text-align:right" | 0.1 |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | 0.1 |
||
| style="text-align:right" | |
|||
| style="text-align:right" | 0.9 |
| style="text-align:right" | 0.9 |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 0.4 |
|||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | 4.0 |
| style="text-align:right" | 4.0 |
||
| style="text-align:right" | |
|||
|} |
|} |
||
</div> |
</div> |
||
==== o/w Grandfathered debt (Economic maturity breakdown) ==== |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t30" class="wikitable fintable" |
||
|+ Economic maturity breakdown – o/w Grandfathered debt |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,393: | Line 1,401: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1,2|2=1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} |
{{fn note|1=1,2|2=1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.}} |
||
{{fn note|1=3|2=3. Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} |
{{fn note|1=3|2=3. Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.}} |
||
</div> |
|||
{{pdf page|33|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|33|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== General Account Invested Assets === |
=== General Account Invested Assets === |
||
* FY25 Total General Account invested assets |
* FY25 Total General Account invested assets |
||
* Duration gap at -0.4 year |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t31" class="wikitable fintable" |
||
|+ FY25 Total General Account invested assets: Euro 450 billion |
|+ FY25 Total General Account invested assets: Euro 450 billion |
||
|- |
|- |
||
| style="text-align:left" | Fixed income |
| style="text-align:left" | Fixed income |
||
| style="text-align:right" | 77% |
|||
|- |
|- |
||
| style="text-align:left" | Real estate |
| style="text-align:left" | Real estate |
||
| style="text-align:right" | 9% |
|||
|- |
|- |
||
| style="text-align:left" | Infrastructure equity |
| style="text-align:left" | Infrastructure equity |
||
| style="text-align:right" | 2% |
|||
|- |
|- |
||
| style="text-align:left" | Listed equities |
| style="text-align:left" | Listed equities |
||
| style="text-align:right" | 2% |
|||
|- |
|- |
||
| style="text-align:left" | Private equity and hedge funds |
| style="text-align:left" | Private equity and hedge funds |
||
| style="text-align:right" | 5% |
|||
|- |
|- |
||
| style="text-align:left" | Cash |
| style="text-align:left" | Cash |
||
| style="text-align:right" | 4% |
|||
|- |
|- |
||
| style="text-align:left" | Policy loans |
| style="text-align:left" | Policy loans |
||
| style="text-align:right" | 0% |
|||
|} |
|} |
||
</div> |
</div> |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t32" class="wikitable fintable" |
||
|+ Invested assets (100%) In Euro billion |
|+ Invested assets (100%) In Euro billion |
||
|- |
|- |
||
| Line 1,475: | Line 1,493: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).}} |
|||
{{fn note|1=1|2=Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).}} |
|||
{{fn note|1=2|2=Includes hedges. Listed equities excluding hedges at Euro 14 billion.}} |
{{fn note|1=2|2=Includes hedges. Listed equities excluding hedges at Euro 14 billion.}} |
||
{{fn note|1=3|2=Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).}} |
{{fn note|1=3|2=Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).}} |
||
{{fn note|1=4|2=Please refer to the financial supplement for more details.}} |
{{fn note|1=4|2=Please refer to the financial supplement for more details.}} |
||
</div> |
|||
{{pdf page|34|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|34|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,484: | Line 1,504: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t33" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | Invested assets (100%)<br/>In Euro billion |
! style="text-align:left" | Invested assets (100%)<br/>In Euro billion |
||
! style="text-align:right" | FY25 |
! class="col-m" style="text-align:right" | FY25 |
||
! style="text-align:right" | % of total G/A{{fn ref|1|2=G/A: General Account}} portfolio |
! class="col-m" style="text-align:right" | % of total G/A{{fn ref|1|2=G/A: General Account}} portfolio |
||
! style="text-align: |
! style="text-align:left" | Comments |
||
|- |
|||
| style="text-align:left" | Residential Mortgages |
|||
| style="text-align:right" | 16 |
|||
| style="text-align:right" | 4% |
|||
| style="text-align:left" | - €6bn Dutch mortgages, NHG guaranteed<br/>- €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
|||
|- |
|||
| style="text-align:left" | CLO & ABS |
|||
| style="text-align:right" | 25 |
|||
| style="text-align:right" | 6% |
|||
| style="text-align:left" | - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) |
|||
|- |
|||
| style="text-align:left" | Infrastructure debt |
|||
| style="text-align:right" | 8 |
|||
| style="text-align:right" | 2% |
|||
| style="text-align:left" | - Skewed towards resilient industries (Telecom, Utilities, Transport) |
|||
|- |
|||
| style="text-align:left" | CRE debt |
|||
| style="text-align:right" | 8 |
|||
| style="text-align:right" | 2% |
|||
| style="text-align:left" | - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV |
|||
|- |
|||
| style="text-align:left" | Mid-Market lending |
|||
| style="text-align:right" | 10 |
|||
| style="text-align:right" | 2% |
|||
| style="text-align:left" | - Strong diversification with €8m average ticket<br/>- Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation |
|||
|- |
|||
| style="text-align:left" | Other |
|||
| style="text-align:right" | 2 |
|||
| style="text-align:right" | 0% |
|||
| style="text-align:left" | |
|||
|- |
|||
| style="text-align:left" | <strong>Total Structured and Private Credit Assets</strong> |
|||
| style="text-align:right" | <strong>69</strong> |
|||
| style="text-align:right" | <strong>15%</strong> |
|||
| style="text-align:left" | o/w 54% participating |
|||
|} |
|} |
||
</div> |
</div> |
||
<tr><td>Residential Mortgages</td><td>16</td><td>4%</td><td>- €6bn Dutch mortgages, NHG guaranteed<br>- €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV)</td></tr> |
|||
<tr><td>CLO & ABS</td><td>25</td><td>6%</td><td>- 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA)</td></tr> |
|||
<tr><td>Infrastructure debt</td><td>8</td><td>2%</td><td>- Skewed towards resilient industries (Telecom, Utilities, Transport)</td></tr> |
|||
<tr><td>CRE debt</td><td>8</td><td>2%</td><td>- Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV</td></tr> |
|||
<tr><td>Mid-Market lending</td><td>10</td><td>2%</td><td>- Strong diversification with €8m average ticket<br>- Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation</td></tr> |
|||
<tr><td>Other</td><td>2</td><td>0%</td><td></td></tr> |
|||
<tr><td><strong>Total Structured and Private Credit Assets</strong></td><td><strong>69</strong></td><td><strong>15%</strong></td><td>o/w 54% participating</td></tr> |
|||
</table> |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=G/A: General Account}} |
{{fn note|1=1|2=G/A: General Account}} |
||
</div> |
|||
{{pdf page|35|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|35|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,507: | Line 1,556: | ||
==== FY25 Fixed Income Reinvestment ==== |
==== FY25 Fixed Income Reinvestment ==== |
||
* Euro 57 billion |
|||
* Government bonds & related (32%) – Average rating: AA |
* Government bonds & related (32%) – Average rating: AA |
||
* Investment grade credit (40%)- Average rating: A |
* Investment grade credit (40%)- Average rating: A |
||
* ABS/CLO/IG fund financing (21%) |
* ABS/CLO/IG fund financing (21%) |
||
* Below investment grade credit (7%) |
* Below investment grade credit (7%) |
||
* Euro 57 billion |
|||
==== FY25 Fixed Income Reinvestment Yield ==== |
==== FY25 Fixed Income Reinvestment Yield ==== |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t34" class="wikitable fintable" |
||
|+ FY25 Fixed Income Reinvestment Yield |
|||
|- |
|- |
||
! style="text-align:left" | Public fixed income{{fn ref|1|2=Government and Corporate bonds and related.}} |
! style="text-align:left" | Public fixed income{{fn ref|1|2=Government and Corporate bonds and related.}} |
||
| Line 1,532: | Line 1,583: | ||
* Euro 57 billion fixed income invested at 3.9% |
* Euro 57 billion fixed income invested at 3.9% |
||
* Average duration of 9 years |
* Average duration of 9 years |
||
* Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) |
* Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY) |
||
* Gradual shift from alternative total return assets to Private & Structured credit |
* Gradual shift from alternative total return assets to Private & Structured credit |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Government and Corporate bonds and related.}} |
{{fn note|1=1|2=Government and Corporate bonds and related.}} |
||
{{fn note|1=2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
{{fn note|1=2|2=Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).}} |
||
</div> |
|||
{{pdf page|36|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|36|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Contents === |
|||
* 1. Debt and Invested Assets p.31 |
* 1. Debt and Invested Assets p.31 |
||
* 2. Additional P&C disclosures p.36 |
* 2. Additional P&C disclosures p.36 |
||
| Line 1,549: | Line 1,604: | ||
==== Well diversified across lines of business and geographies ==== |
==== Well diversified across lines of business and geographies ==== |
||
* $19bn FY25 GWP by line of business |
|||
<div style="overflow-x:auto"> |
|||
* Casualty (35%) |
|||
{| id="t38" class="wikitable fintable" |
|||
* Property (29%) |
|||
|+ $19bn FY25 GWP by line of business |
|||
* Specialty (19%) |
|||
|- |
|||
* Professional lines{{fn ref|1|2=Including Cyber}} (17%) |
|||
| style="text-align:left" | Casualty |
|||
| style="text-align:right" | 35% |
|||
|- |
|||
| style="text-align:left" | Property |
|||
| style="text-align:right" | 29% |
|||
|- |
|||
| style="text-align:left" | Specialty |
|||
| style="text-align:right" | 19% |
|||
|- |
|||
| style="text-align:left" | Professional lines{{fn ref|1|2=Including Cyber}} |
|||
| style="text-align:right" | 17% |
|||
|} |
|||
</div> |
|||
* $19bn FY25 GWP by geography |
|||
<div style="overflow-x:auto"> |
|||
* Americas (46%) |
|||
{| id="t39" class="wikitable fintable" |
|||
* Europe & APAC (35%) |
|||
|+ $19bn FY25 GWP by geography |
|||
* UK & Lloyds (19%) |
|||
|- |
|||
| style="text-align:left" | Americas |
|||
| style="text-align:right" | 46% |
|||
|- |
|||
| style="text-align:left" | Europe & APAC |
|||
| style="text-align:right" | 35% |
|||
|- |
|||
| style="text-align:left" | UK & Lloyds |
|||
| style="text-align:right" | 19% |
|||
|} |
|||
</div> |
|||
==== Leading market positions across lines ==== |
==== Leading market positions across lines ==== |
||
* Top 3 globally |
* Top 3 globally |
||
* Multinational Programs{{fn ref|2|2=Source: McKinsey}} |
* Multinational Programs{{fn ref|2|2=Source: McKinsey}} |
||
* Marine{{fn ref|3|2=Source: Aon, Guy Carpenter, and Global Market Insights}} |
* Marine{{fn ref|3|2=Source: Aon, Guy Carpenter, and Global Market Insights}} |
||
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026)}} |
* Fine Art & Specie{{fn ref|4|2=Source: Industry Research Biz (January 2026)}} |
||
==== Managing the cycle to deliver consistent profitability ==== |
==== Managing the cycle to deliver consistent profitability ==== |
||
* Bubble chart with axes: Ex-price growth (%) (x-axis) and Profitability (y-axis); segments shown: Property (high profitability, high ex-price growth), Specialty, Casualty, Professional lines (lower profitability, lower ex-price growth) |
|||
* Profitability vs. Ex-price growth (%) |
|||
* Professional lines (Lower ex-price growth, lower profitability) |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
* Casualty (Medium ex-price growth, medium profitability) |
|||
* Specialty (Medium-high ex-price growth, medium-high profitability) |
|||
* Property (High ex-price growth, high profitability) |
|||
{{fn note|1=1|2=Including Cyber}} |
{{fn note|1=1|2=Including Cyber}} |
||
{{fn note|1=2|2=Source: McKinsey}} |
{{fn note|1=2|2=Source: McKinsey}} |
||
{{fn note|1=3|2=Source: Aon, Guy Carpenter, and Global Market Insights}} |
{{fn note|1=3|2=Source: Aon, Guy Carpenter, and Global Market Insights}} |
||
{{fn note|1=4|2=Source: Industry Research Biz (January 2026)}} |
{{fn note|1=4|2=Source: Industry Research Biz (January 2026)}} |
||
</div> |
|||
{{pdf page|38|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|38|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,608: | Line 1,643: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t35" class="wikitable fintable" |
||
|+ Claims reserves ratio |
|+ Claims reserves ratio |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,616: | Line 1,651: | ||
! class="col-s" style="text-align:right" | FY20 |
! class="col-s" style="text-align:right" | FY20 |
||
! class="col-s" style="text-align:right" | FY21 |
! class="col-s" style="text-align:right" | FY21 |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 (IFRS4) |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 (IFRS17) |
||
! class="col-s" style="text-align:right" | FY23 |
! class="col-s" style="text-align:right" | FY23 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
! style="text-align:left" | |
|||
! colspan="5" style="text-align:center" | IFRS4 |
|||
! colspan="4" style="text-align:center" | IFRS17 |
|||
|- |
|- |
||
| style="text-align:left" | Claims reserves ratio |
| style="text-align:left" | Claims reserves ratio |
||
| Line 1,643: | Line 1,674: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t36" class="wikitable fintable" |
||
|+ Technical reserves ratio |
|+ Technical reserves ratio |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,651: | Line 1,682: | ||
! class="col-s" style="text-align:right" | FY20 |
! class="col-s" style="text-align:right" | FY20 |
||
! class="col-s" style="text-align:right" | FY21 |
! class="col-s" style="text-align:right" | FY21 |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 (IFRS4) |
||
! class="col-s" style="text-align:right" | FY22 |
! class="col-s" style="text-align:right" | FY22 (IFRS17) |
||
! class="col-s" style="text-align:right" | FY23 |
! class="col-s" style="text-align:right" | FY23 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|||
! style="text-align:left" | |
|||
! colspan="5" style="text-align:center" | IFRS4 |
|||
! colspan="4" style="text-align:center" | IFRS17 |
|||
|- |
|- |
||
| style="text-align:left" | Technical reserves ratio |
| style="text-align:left" | Technical reserves ratio |
||
| Line 1,674: | Line 1,701: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Includes net undiscounted claims reserves and unearned premium reserves.}} |
{{fn note|1=1|2=Includes net undiscounted claims reserves and unearned premium reserves.}} |
||
</div> |
|||
{{pdf page|39|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|39|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,680: | Line 1,709: | ||
* In Euro |
* In Euro |
||
==== Insurance segment (occurrence protection) ==== |
|||
==== Reinsurance segment (illustrative) ==== |
|||
* Alternative Capital & Cat Bonds |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t37" class="wikitable fintable" |
||
|+ Insurance segment (occurrence protection) |
|+ Insurance segment (occurrence protection) / Reinsurance segment (illustrative) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,698: | Line 1,721: | ||
! class="col-s" style="text-align:right" | NA Earthquake |
! class="col-s" style="text-align:right" | NA Earthquake |
||
! class="col-s" style="text-align:right" | Per other perils{{fn ref|3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
! class="col-s" style="text-align:right" | Per other perils{{fn ref|3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
||
! style="text-align:left" | Reinsurance segment (illustrative) — Alternative Capital & Cat Bonds |
|||
|- |
|- |
||
| style="text-align:left" | Capacity |
| style="text-align:left" | Capacity |
||
| Line 1,706: | Line 1,730: | ||
| style="text-align:right" | 1.2bn |
| style="text-align:right" | 1.2bn |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:left" | |
|||
|- |
|- |
||
| style="text-align:left" | Retention |
| style="text-align:left" | Retention |
||
| Line 1,714: | Line 1,739: | ||
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
| style="text-align:right" | 600m{{fn ref|2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
||
| style="text-align:right" | 400m |
| style="text-align:right" | 400m |
||
| style="text-align:left" | |
|||
|} |
|} |
||
</div> |
</div> |
||
| Line 1,719: | Line 1,745: | ||
* Stable retention levels maintained in 2026 as in 2025 |
* Stable retention levels maintained in 2026 as in 2025 |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Excludes local reinsurance covers;}} |
{{fn note|1=1|2=Excludes local reinsurance covers;}} |
||
{{fn note|1=2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
{{fn note|1=2|2=Varying retention between MX and NA (400m MX, 600m NA);}} |
||
{{fn note|1=3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
{{fn note|1=3|2=Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.}} |
||
</div> |
|||
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|40|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). Full Year 2025 Earnings}} in 2026 === |
=== P&C – AXA Group earnings deviation with different levels of Nat Cat cost{{fn ref|1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). Full Year 2025 Earnings}} in 2026 === |
||
In Euro billion (net of reinsurance) |
* In Euro billion (net of reinsurance) |
||
==== Group underlying earnings deviation to average Nat Cat charges in 2026 ==== |
==== Group underlying earnings deviation to average Nat Cat charges in 2026 ==== |
||
net of reinsurance, post-tax | net of reinsurance, pre-tax |
* net of reinsurance, post-tax | net of reinsurance, pre-tax |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t38" class="wikitable" |
||
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 |
|+ Group underlying earnings deviation to average Nat Cat charges in 2026 (net of reinsurance, post-tax) |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | Scenario |
||
! style="text-align:right" | |
! style="text-align:right" | Percentile |
||
! style="text-align:right" | Deviation |
! style="text-align:right" | Deviation |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 1/20y more severe |
||
| style="text-align:right" | |
| style="text-align:right" | 95th |
||
| style="text-align:right" | €-1.2bn |
| style="text-align:right" | €-1.2bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 1/10y more severe |
||
| style="text-align:right" | |
| style="text-align:right" | 90th |
||
| style="text-align:right" | €-0.8bn |
| style="text-align:right" | €-0.8bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 1/5y more severe |
||
| style="text-align:right" | |
| style="text-align:right" | 80th |
||
| style="text-align:right" | €-0.4bn |
| style="text-align:right" | €-0.4bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Median |
||
| style="text-align:right" | |
| style="text-align:right" | 50th |
||
| style="text-align:right" | €+0.1bn |
| style="text-align:right" | €+0.1bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 1/5y less severe |
||
| style="text-align:right" | |
| style="text-align:right" | 20th |
||
| style="text-align:right" | €+0.5bn |
| style="text-align:right" | €+0.5bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 1/10y less severe |
||
| style="text-align:right" | |
| style="text-align:right" | 10th |
||
| style="text-align:right" | €+0.7bn |
| style="text-align:right" | €+0.7bn |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | 1/20y less severe |
||
| style="text-align:right" | |
| style="text-align:right" | 5th |
||
| style="text-align:right" | €+0.8bn |
| style="text-align:right" | €+0.8bn |
||
|} |
|} |
||
| Line 1,771: | Line 1,799: | ||
* More severe years — Negative deviation in ca. 40% of cases |
* More severe years — Negative deviation in ca. 40% of cases |
||
* Less severe years — Positive deviation in ca. 60% of cases |
* Less severe years — Positive deviation in ca. 60% of cases |
||
| Line 1,776: | Line 1,805: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t39" class="wikitable" |
||
|+ Average Expected Nat Cat charges (net of reinsurance, pre-tax) |
|+ Average Expected Nat Cat charges (net of reinsurance, pre-tax) |
||
|- |
|- |
||
| Line 1,783: | Line 1,812: | ||
! style="text-align:right" | 2026 |
! style="text-align:right" | 2026 |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | Amount (€bn) |
||
| style="text-align:right" | 2.6 |
| style="text-align:right" | 2.6 |
||
| style="text-align:right" | 2.7 |
| style="text-align:right" | 2.7 |
||
| Line 1,793: | Line 1,822: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). Full Year 2025 Earnings}} |
{{fn note|1=1|2=Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). Full Year 2025 Earnings}} |
||
</div> |
|||
{{pdf page|41|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|41|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Contents === |
|||
* 1. Debt and Invested Assets p.31 |
* 1. Debt and Invested Assets p.31 |
||
* 2. Additional P&C disclosures p.36 |
* 2. Additional P&C disclosures p.36 |
||
| Line 1,807: | Line 1,839: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t40" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col- |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | <strong>Current Accident Year Undiscounted Technical Margin</strong> |
| style="text-align:left" | <strong>Current Accident Year Undiscounted Technical Margin</strong> |
||
| style="text-align:right" | 2,778 |
| style="text-align:right" | 2,778 |
||
| style="text-align:right" | +707 |
| style="text-align:right" | +707 |
||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
|||
{| id="t41" class="wikitable fintable" |
|||
|- |
|- |
||
| style="text-align:left" | Gross Earned Premiums |
| style="text-align:left" | Gross Earned Premiums |
||
| Line 1,825: | Line 1,862: | ||
| style="text-align:right" | -1.0pt |
| style="text-align:right" | -1.0pt |
||
|- |
|- |
||
| style="text-align:left" | |
| style="text-align:left" | o/w Nat Cats |
||
| style="text-align:right" | |
| style="text-align:right" | 3.4% |
||
| style="text-align:right" | |
| style="text-align:right" | -0.4pt |
||
|} |
|} |
||
</div> |
</div> |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t42" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,861: | Line 1,898: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t43" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,877: | Line 1,914: | ||
</div> |
</div> |
||
<div style="overflow-x:auto"> |
|||
* FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
|||
{| id="t44" class="wikitable" |
|||
* +25bps: €+0.2bn |
|||
|+ FY25 sensitivity to Current Accident Year discount rate changes{{fn ref|2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
|||
* -25bps: €-0.2bn |
|||
|- |
|||
! style="text-align:left" | +25bps |
|||
! style="text-align:right" | -25bps |
|||
|- |
|||
| style="text-align:left" | €+0.2bn |
|||
| style="text-align:right" | €-0.2bn |
|||
|} |
|||
</div> |
|||
 #### Financial Result |
|||
In Euro million (pre-tax) |
In Euro million (pre-tax) |
||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t45" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,910: | Line 1,955: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t46" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,930: | Line 1,975: | ||
</div> |
</div> |
||
<div style="overflow-x:auto"> |
|||
* 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn |
|||
{| id="t47" class="wikitable" |
|||
* Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount |
|||
|+ 2026e Insurance Finance Expenses (pre-tax): ~ €-1.4bn — Sensitivity of 2026e Insurance Finance Expenses to changes in 2025 current AY Discount |
|||
* +25bps: ~ €-50m |
|||
|- |
|||
* -25bps: ~€+50m |
|||
! style="text-align:left" | +25bps |
|||
! style="text-align:right" | -25bps |
|||
|- |
|||
| style="text-align:left" | ~ €-50m |
|||
| style="text-align:right" | ~€+50m |
|||
|} |
|||
</div> |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t48" class="wikitable fintable" |
||
|+ Full Year 2025 Earnings |
|||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | <strong>Underlying Earnings before tax</strong> |
| style="text-align:left" | <strong>Underlying Earnings before tax</strong> |
||
| Line 1,960: | Line 2,013: | ||
| style="text-align:left" | <em>Growth vs. FY24 (at constant FX)</em> |
| style="text-align:left" | <em>Growth vs. FY24 (at constant FX)</em> |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | |
| style="text-align:right" | +9% |
||
|} |
|} |
||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
||
{{fn note|1=2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
{{fn note|1=2|2=Parallel shift of the full-year average yield curve (average of monthly opening discount rates of 2025) used for discounting FY25 current accident year net reserve.}} |
||
</div> |
|||
{{pdf page|43|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|43|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 1,976: | Line 2,031: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t49" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
| Line 1,982: | Line 2,037: | ||
! class="col-s" style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <strong>Short-term Technical Margin</strong> |
||
| style="text-align:right" | |
| style="text-align:right" | 479 |
||
| style="text-align:right" | |
| style="text-align:right" | +60 |
||
|- |
|- |
||
| style="text-align:left" | Gross Earned Premiums |
| style="text-align:left" | Gross Earned Premiums |
||
| Line 1,995: | Line 2,050: | ||
|} |
|} |
||
</div> |
</div> |
||
* Incl. recapture of Laya |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t50" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! class="col- |
! class="col-s" style="text-align:right" | FY25 |
||
! class="col- |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <strong>Long-term Technical Margin</strong> |
||
| style="text-align:right" | |
| style="text-align:right" | 2,804 |
||
| style="text-align:right" | |
| style="text-align:right" | +156 |
||
|- |
|- |
||
| style="text-align:left" | CSM release |
| style="text-align:left" | CSM release |
||
| Line 2,016: | Line 2,073: | ||
|} |
|} |
||
</div> |
</div> |
||
* Incl. recapture of Laya |
|||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t51" class="wikitable fintable" |
||
|+ Life & Health FY25 CSM Key Sensitivities |
|+ Life & Health FY25 CSM Key Sensitivities (in Euro billion) |
||
|- |
|||
! style="text-align:left" | Baseline |
|||
! class="col-s" style="text-align:right" | 33.3 |
|||
|- |
|||
| style="text-align:left" | Interest rates +50bps |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | Interest rates -50bps |
|||
| style="text-align:right" | 0.6 |
|||
|- |
|||
| style="text-align:left" | Sovereign spreads +50bps |
|||
| style="text-align:right" | -1.9 |
|||
|- |
|||
| style="text-align:left" | Sovereign spreads -50bps |
|||
| style="text-align:right" | 1.9 |
|||
|- |
|||
| style="text-align:left" | Corporate spread +50bps |
|||
| style="text-align:right" | -0.8 |
|||
|- |
|||
| style="text-align:left" | Corporate spread -50bps |
|||
| style="text-align:right" | 0.7 |
|||
|- |
|||
| style="text-align:left" | Equities +25% |
|||
| style="text-align:right" | 1.8 |
|||
|- |
|||
| style="text-align:left" | Equities -25% |
|||
| style="text-align:right" | -2.2 |
|||
|} |
|} |
||
</div> |
</div> |
||
(in Euro billion)</caption> |
|||
<tr><th></th><th>FY25</th></tr> |
|||
<tr><td><b>Baseline</b></td><td>33.3</td></tr> |
|||
<tr><td>Interest rates +50bps</td><td>-0.8</td></tr> |
|||
<tr><td>Interest rates -50bps</td><td>0.6</td></tr> |
|||
<tr><td>Sovereign spreads +50bps</td><td>-1.9</td></tr> |
|||
<tr><td>Sovereign spreads -50bps</td><td>1.9</td></tr> |
|||
<tr><td>Corporate spread +50bps</td><td>-0.8</td></tr> |
|||
<tr><td>Corporate spread -50bps</td><td>0.7</td></tr> |
|||
<tr><td>Equities +25%</td><td>1.8</td></tr> |
|||
<tr><td>Equities -25%</td><td>-2.2</td></tr> |
|||
</table> |
|||
==== Financial Result ==== |
==== Financial Result ==== |
||
| Line 2,041: | Line 2,111: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t52" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <strong>Investment Income (non-VFA only)</strong> |
||
| style="text-align:right" | |
| style="text-align:right" | 2,484 |
||
| style="text-align:right" | |
| style="text-align:right" | -1 |
||
|- |
|- |
||
| style="text-align:left" | FY25 Average Assets |
| style="text-align:left" | FY25 Average Assets |
||
| Line 2,066: | Line 2,136: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t53" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <strong>Insurance Finance Expenses (non-VFA only)</strong> |
||
| style="text-align:right" | |
| style="text-align:right" | -1,538 |
||
| style="text-align:right" | |
| style="text-align:right" | -9 |
||
|- |
|- |
||
| style="text-align:left" | FY24 Reserves at locked-in rate |
| style="text-align:left" | FY24 Reserves at locked-in rate |
||
| Line 2,087: | Line 2,157: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t54" class="wikitable fintable" |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! style="text-align:right" | Change |
! class="col-s" style="text-align:right" | Change |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <strong>Underlying Earnings before tax</strong> |
||
| style="text-align:right" | |
| style="text-align:right" | 4,229 |
||
| style="text-align:right" | |
| style="text-align:right" | +205 |
||
|- |
|- |
||
| style="text-align:left" | Tax |
| style="text-align:left" | Tax |
||
| Line 2,105: | Line 2,175: | ||
| style="text-align:right" | -51 |
| style="text-align:right" | -51 |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <strong>Underlying Earnings</strong> |
||
| style="text-align:right" | |
| style="text-align:right" | 3,501 |
||
| style="text-align:right" | |
| style="text-align:right" | +219 |
||
|- |
|- |
||
| style="text-align:left" | < |
| style="text-align:left" | <em>Growth vs. FY24 (at constant FX)</em> |
||
| style="text-align:right" | |
| style="text-align:right" | |
||
| style="text-align:right" | +7% |
| style="text-align:right" | +7% |
||
| Line 2,115: | Line 2,185: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
{{fn note|1=1|2=Reinvestment yield on fixed income assets.}} |
||
</div> |
|||
{{pdf page|44|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|44|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Contents === |
|||
* 1. Debt and Invested Assets p.31 |
* 1. Debt and Invested Assets p.31 |
||
* 2. Additional P&C disclosures p.36 |
* 2. Additional P&C disclosures p.36 |
||
| Line 2,126: | Line 2,199: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| id=" |
{| id="t55" class="wikitable" |
||
|- |
|- |
||
! colspan="2" style="text-align:center" | As a GLOBAL INVESTOR |
! colspan="2" style="text-align:center" | As a GLOBAL INVESTOR |
||
| Line 2,161: | Line 2,234: | ||
</div> |
</div> |
||
<div class="ed-fn-notes" style="display:none"> |
|||
{{fn note|1=1|2=AXA's Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group's auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} |
{{fn note|1=1|2=AXA's Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group's auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.}} |
||
{{fn note|1=2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} |
{{fn note|1=2|2=Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.}} |
||
| Line 2,169: | Line 2,243: | ||
{{fn note|1=7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} |
{{fn note|1=7|2=Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.}} |
||
{{fn note|1=8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}} |
{{fn note|1=8|2=Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).}} |
||
</div> |
|||
{{pdf page|46|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|46|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Sustainability Performance & Ratings === |
=== Sustainability Performance & Ratings === |
||
* S&P Global: 2025 percentile: 97th{{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices |
|||
* MSCI: 2025 score: AAA |
|||
* CDP: 2025 score: B |
|||
* Morningstar Sustainalytics: 2025 ESG Risk Rating: 17.0– Low risk |
|||
* FTSE Russell: 2025 score: 4.3/5 in FTSE4Good Index Series |
|||
<div class="ed-fn-notes" style="display:none"> |
|||
* 2025 percentile: 97th {{fn ref|1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} in Dow Jones Best-in-Class Europe & World indices |
|||
* 2025 score: AAA |
|||
* 2025 score: B |
|||
* 2025 ESG Risk Rating: 17.0– Low risk |
|||
* 2025 score: 4.3/5 in FTSE4Good Index Series |
|||
{{fn note|1=1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} |
{{fn note|1=1|2=The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.}} |
||
</div> |
|||
{{pdf page|47|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|47|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
| Line 2,214: | Line 2,287: | ||
{{pdf page|49|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
{{pdf page|49|url=https://www-axa-com.cdn.prismic.io/www-axa-com/abwhxx5fn6DF3AUJ_AXA_Full_Year_Results_2025b.pdf}} |
||
=== Thank you === |
=== Thank you Full Year 2025 Earnings February 26, 2026 === |
||
* Full Year 2025 Earnings |
|||
* February 26, 2026 |
|||
Revision as of 17:01, 22 July 2026
| Document info | |
|---|---|
| Document ID | snjra2xp9r |
| Organization | AXA |
| Year | 2025 |
| Period | FY |
| Period label | FY25 |
| Document category | Earnings presentation |
| Document name | AXA Full Year 2025 Results Presentation |
| Publication date | 2026-02-26 |
| Language | English |
| Pages | 49 |
| Source | original URL |
| Summary | wiki page |
Full Year 2025 Earnings Presentation February 26, 2026
Full Year 2025 Earnings
- GIE_AXA_Internal 2 Full Year 2025 Earnings
- IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS AND THE USE OF NON-GAAP FINANCIAL MEASURES
- Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans, expectations or objectives, and other information that is not historical information. Forward-looking statements are generally identified by words and expressions such as “expects”, “anticipates”, “may”, “plan,” “target” or any variations or similar terminology of these words and expressions, or conditional verbs such as, without limitations, “would” and “could”. In particular, the statements in this presentation regarding expected underlying earnings per share (“UEPS”) growth for 2026 are forward-looking statements to provide one-off guidance in the context of the last year of the Group’s current strategic plan. These statements in this presentation are based on Management’s current views and intentions and are subject to change. Undue reliance should not be placed on forward-looking statements because, by their nature, they are subject to known and unknown risks and uncertainties, many of which are outside AXA’s control, and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed in, or implied or projected by, such forward-looking statements. Each forward-looking statement speaks only at the date of this presentation. Please refer to Part 5 - “Risk Factors and Risk Management” of AXA’s Universal Registration Document for the year ended December 31, 2024 (the “2024 Universal Registration Document”) for a description of certain important factors, risks and uncertainties that may affect AXA’s business and/or results of operations. AXA specifically disclaims and undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as required by applicable laws and regulations.
- In addition, this presentation refers to certain non-GAAP financial measures, or alternative performance measures (“APMs”), used by Management in analyzing AXA’s operating trends, financial performance and financial position and providing investors with additional information that Management believes to be useful and relevant regarding AXA’s results. These non-GAAP financial measures generally have no standardized meaning and therefore may not be comparable to similarly labelled measures used by other companies. As a result, none of these non-GAAP financial measures should be considered in isolation from, or as a substitute for, the Group’s consolidated financial statements and related notes prepared in accordance with IFRS. “Underlying earnings”, UEPS (“underlying earnings per share”), “underlying return on equity”, “combined ratio” and “debt gearing” are APMs as defined in ESMA’s guidelines and the AMF’s related position statement issued in 2015. AXA provides a reconciliation of such APMs to the most closely related line item, subtotal, or total in the financial statements of the corresponding period (and/or their calculation methodology, as applicable) in its Activity Report as of December 31, 2025 (“AXA’s 2025 Activity Report”), on the pages indicated under the heading “USE OF NON-GAAP AND ALTERNATIVE PERFORMANCE MEASURES”. For further information on the above-mentioned and other non-GAAP financial measures used in this presentation, see the Glossary in AXA’s 2025 Activity Report.
- AXA’s Activity Report as of December 31, 2025 is available on the AXA Group website (www.axa.com).
- AXA’s consolidated financial statements for the year ended December 31, 2025 were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA’s statutory auditors.
Contents
- 1. FY25 Highlights p.04
- Thomas Buberl, Group CEO
- 2. FY25 Business Performance p.09
- Guillaume Borie, Global Head of Finance, Strategy, Underwriting, Risk, and Technology
- 3. FY25 Financial Performance p.13
- Alban de Mailly Nesle, Group CFO
FY25 Highlights
- Thomas Buberl, Group CEO
Full Year 2025 – Excellent performance
- +6% Revenues vs. FY24
- +8% Underlying EPS vs. FY24
- 16% ROE — FY25
- 224% Solvency II ratio — FY25
- Delivering value for shareholders +8% DPS1(footnote: Based on the dividend proposed by AXA's Board of Directors on February 25, 2026 and subject to approval by the Shareholders' Annual General Meeting to be held on April 30, 2026.) growth and €1.25bn annual share buy back2(footnote: Following AXA's Board of Directors' approval on February 25, 2026, and expected to commence as soon as reasonably practicable, subject to market conditions.)
- Confident to deliver underlying EPS growth at the upper end of 6%-8% target range for 2026
Executing the plan on growth, margin and efficiency
| FY24 | FY25 | Change | |
|---|---|---|---|
| Underlying earnings | 8.1 | 8.4 | +6% |
| Underlying earnings excluding AXA IM | +9% |
- High organic growth: +6% top line growth, well balanced across lines (P&C: +5%, Life: +9%, Health: +5%)
- Record profitability: Further margin expansion in P&C and L&H; improvement in efficiency
- Scaling the business: Continued investments in growth and technology
- Consistent earnings growth while enhancing reserve prudence
Diversified franchise, well positioned in an attractive industry
Secular trends fueling demand across businesses
- Protection gaps and emerging corporate risks
- Demographics driving demand for private retirement and healthcare
| Segment | Share |
|---|---|
| Life | 33% |
| Health | 17% |
| Large & Specialty | 17% |
| SME & Mid-market | 16% |
| Retail | 17% |
Our right to win
- Leading brand & high customer NPS
- Strong and diversified distribution
- Technical expertise to price & underwrite risks
- Scale offering cost advantage
Laying the foundation for the next plan
- Clear tech and AI roadmap
- Driving efficiency
- Enhancing capital allocation discipline
- Building resilience
- Confidence in sustaining earnings growth
FY25 Business Performance
- Guillaume Borie
- Global Head of Finance, Strategy, Underwriting, Risk, and Technology
Strong delivery across our businesses
| Gross written premiums | Underlying earnings | |
|---|---|---|
| France (27% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +6% to €31bn | +7% to €2.2bn |
| Europe (38% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +6% to €43bn | +9% to €3.5bn |
| AXA XL (17% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +4% to €19bn | +9% to €1.9bn |
| Asia, Africa & EME-LATAM (18% of total GWP1(footnote: FY25 gross written premiums excluding AXA IM, Holdings, AXA Assistance, and AXA Liabilities Managers.)) | +13% to €20bn | +6% to €1.5bn |
P&C – Strong margins, confidence in sustaining growth
- €58bn GWP
- GWP mix: Retail, SME & Mid-market, AXA XL1(footnote: Includes AXA XL Re premiums of €2.6bn.) (Large & Specialty) — shares not printed
- Underlying earnings +9%2(footnote: Change FY25 vs. FY24 at constant FX.) to €5.9bn
| 2025 | Beyond 2025 | |
|---|---|---|
| Retail and SME & Mid-market | Growing volumes while expanding margins | Investing to improve customer retention & expanding distribution footprint |
| AXA XL (Large & Specialty) | Profitable growth with stable margins | Capitalizing on attractive growth opportunities and continued cycle management |
- Continued progress on efficiency
- Higher investment income
- Data & AI to further enhance customer experience & technical excellence
L&H – Good momentum, well positioned to capture growth opportunities
| Short-term | |
| Long-term | |
| Total GWP | €57bn |
- Underlying earnings +7%1(footnote: 1. Change FY25 vs. FY24 at constant FX.) to €3.5bn
2025 Beyond 2025
- Long-term business
- Accelerating net flows in Savings at attractive margins
- Capturing savings & retirement opportunity, sourcing best asset management products for our customers
- Short-term business
- Growing technical results while absorbing Mexico VAT impact
- Capitalizing on demand for health & protection while further improving our margins
- Focus on cost reduction
- Increasing penetration of Protection riders in Savings offerings
- Leveraging AI to reduce claims leakage & improve customer outcomes in Health
FY25 Financial Performance
- Alban de Mailly Nesle
- Group CFO
P&C – Continued disciplined growth
- In Euro billion
GWP & Other Revenues
| Segment | FY24 | FY25 | Change | o/w pricing1(footnote: Price effect.) | o/w volume2(footnote: Includes exposure adjustments and mix & other effects.) |
|---|---|---|---|---|---|
| Commercial lines | 35.8 | +4% | +2% | +2% | |
| AXA XL Reinsurance | 2.6 | +8% | +0.3% | +7% | |
| Retail lines | 19.7 | +7% | +5% | +2% | |
| Total | 56.5 | 58.0 | +5% |
- Continued pricing momentum and volume growth in Mid-market and SME
- Growing in lines of business with attractive margins while remaining focused on retention at AXA XL Insurance
- Growth supported by alternative capital
- Favorable pricing trends and strong growth in net new contracts (+1.7m in FY25)
P&C – Delivering further margin expansion while enhancing reserve prudence
Combined ratio
| FY24 | FY25 | |
|---|---|---|
| Combined ratio | 91.0% | 90.6% |
| Undiscounted CY loss ratio (ex Nat Cat) | 67.4% | 67.0% |
| Expense ratio | 25.0% | 24.8% |
| Nat Cat | 3.8% | 3.4% |
| Prior year reserve development | -1.6% | -1.1% |
| Discount | -3.6% | -3.5% |
- Better undiscounted current year loss ratio excluding Nat Cat from:
- Margin expansion in Commercial lines SME & mid-market business and Personal lines reflecting favorable pricing environment
- Stable AXA XL Insurance margins at attractive levels reflecting disciplined cycle management
- Improvement in expense ratio reflecting the impact of efficiency measures, while continuing to invest in growth initiatives and technology
- Nat Cat charges below normalized load
- Lower reliance on prior year reserve development
- Taking advantage of a good year to enhance reserve prudence
P&C – Earnings growth from higher underwriting and financial result
In Euro million
| Step | Value |
|---|---|
| FY24 | 5,510 |
| Volume growth ( Underwriting result1(footnote: Underwriting result includes expenses.)) | +292 |
| Margin improvement | +189 |
| Investment income ( Financial result) | +435 |
| Insurance finance expenses | -235 |
| Tax | -169 |
| Affiliates, FX & other | -150 |
| FY25 | 5,872 |
- +9%
- Better underwriting result from strong volume growth and improved all-year combined ratio while enhancing reserve prudence
- Increase in investment income reflecting higher volumes and better reinvestment yields on fixed income assets
- Higher unwind of discount of claims reserves, in line with guidance
- Unfavorable forex impact notably due to USD depreciation vs. EUR
- In Euro billion
| FY24 | FY25 | Growth | |
|---|---|---|---|
| Total | 34.5 | 37.5 | +9% |
| Protection | 17.3 | +11% | |
| Unit-Linked | 9.3 | +13% | |
| Capital light G/A | 9.0 | +7% | |
| Traditional G/A | 1.9 | -7% |
| FY24 | FY25 | Growth | |
|---|---|---|---|
| Total | 17.5 | 19.0 | +5% |
| Individual | 10.5 | +6% | |
| Group | 8.5 | +4% |
| Segment | Net flows |
|---|---|
| Protection | +4.9 |
| Health | +2.7 |
| Unit-Linked | +1.5 |
| Capital light G/A | +1.2 |
| Traditional G/A | -5.0 |
- o/w FY25 Employee Benefits1(footnote: Including both short-term and long-term Employee Benefits GWP and other revenues.)
- Euro 12.9 billion (+4% vs. FY24) Change at constant scope and FX.
Life & Health – Strong volume growth in Savings and Protection impacted by higher interest rates on discounting
| FY24 | FY25 | |
|---|---|---|
| Protection & Health | 31.4 | |
| Unit-Linked | 8.5 | |
| Capital-light G/A | 7.8 | |
| Traditional G/A | 1.7 | |
| Total | 50.9 | 49.4 |
| Change | -2% | |
| Protection & Health change | -4% | |
| Unit-Linked change | +18% | |
| Capital-light G/A change | -10% | |
| Traditional G/A change | -10% | |
| FY24 | FY25 |
|---|---|
| 2.2 | 2.2 |
| +3% | |
| FY24 | FY25 |
|---|---|
| 2.3 | 2.2 |
| stable | |
| NBV margin 4.4% | 4.5% |
- PVEP was impacted by higher interest rates on discounting despite strong growth in Life volumes
- NB CSM was driven by robust Savings & Protection sales, with reported growth impacted by higher interest rates for discounting of future profits
- NBV was broadly stable as strong growth in NB CSM balanced lower contribution from short-term multinational business in France
- Change at constant scope and FX.
Life & Health – Growth in new business driving Normalized CSM growth
- In Euro billion
Contractual Service Margin rollforward
| FY24 | New business CSM | Underlying return on in-force | CSM release | Economic variance | Operating variance | Affiliates, FX & other | FY25 |
|---|---|---|---|---|---|---|---|
| 33.6 | +2.2 | +1.3 | -3.0 | +0.6 | -0.3 | -1.4 | 33.0 |
| Normalized CSM growth +2% | |||||||
- o/w Life: 25.8 (FY24) → 25.4 (FY25)
- o/w Health: 7.7 (FY24) → 7.6 (FY25)
- Normalized CSM up by +2%, with CSM release growth reflecting better margins and new business CSM growth impacted by higher rates
- Economic variance reflecting government spreads tightening and positive equity market returns
- Operating variance driven by better margins and net flows that were more than offset by a reduction in the duration of Group Life business in Switzerland
- FX impact mainly from JPY and HKD depreciation
Life & Health – Strong momentum in both short-term and long-term business
In Euro million
Underlying Earnings +7%
| Step | Value |
|---|---|
| FY24 | 3,323 |
| Short-term technical margin | +60 |
| Long-term result incl. CSM release | +156 |
| Financial result | -11 |
| Tax, FX and others | -27 |
| FY25 | 3,501 |
| FY24 | FY25 | |
|---|---|---|
| Short-term technical margin | 415 | 479 |
| Long-term result incl. CSM release | 2,680 | 2,804 |
| Financial result | 975 | 946 |
| Tax & others | -748 | -728 |
- o/w Life: 2.6 → 2.7 in billions — +4% vs. FY24
- o/w Health: 0.7 → 0.8 in billions — +17% vs. FY24
- Strong short-term technical margin reflecting underwriting and claims initiatives that more than offset the impact of legislative change on the recoverability of value added tax in Mexico (€-0.1bn)
- Higher long-term results from increase in CSM release (+8%) reflecting growth in reserve base, including from favorable equity market performance, and better margins
Growth in net income reflecting higher earnings & the gain from the sale of AXA IM
| FY24 | FY25 | Change | |
|---|---|---|---|
| Property & Casualty | 5.5 | 5.9 | +9% |
| Life & Health | 3.3 | 3.5 | +7% |
| Asset Management | 0.4 | 0.2 | -57% |
| Holdings & other | -1.2 | -1.2 | - |
| Underlying earnings | 8.1 | 8.4 | +6% |
| Non-financial flows | -0.5 | +2.1 | |
| o/w capital gains from AXA IM disposal | - | +2.2 | |
| Financial flows (incl. RCG) | +0.3 | -0.7 | |
| Net income | 7.9 | 9.8 | +26% |
- Underlying earnings
- Strong performance from insurance businesses
- Stable holding cost, expected to remain at current level in 2026
- Net Income
- Higher net income mainly reflecting higher underlying earnings and the gain from the sale of AXA IM
- Lower financial flows reflecting unfavorable forex impact
In Euro
| FY24 | FY25 | Change |
|---|---|---|
| 3.59 | 3.86 | +8% |
- +6% from earnings growth
- +3% from capital management
- -2% from forex
- including -1% from temporary earnings dilution from AXA IM sale due to the timing of anti-dilutive share buyback
- In Euro billion
| FY24 | HY25 | FY25 | |
|---|---|---|---|
| SHE (excl. OCI) | 58.0 | 52.7 | 54.0 |
| Net OCI | -8.1 | -7.2 | -6.8 |
| Shareholders' Equity | 49.9 | 45.5 | 47.2 |
| SHE (excl. OCI & undated subordinated debt) | 53.2 | 47.0 | 49.4 |
| Debt gearing | 20.6% | 23.4% | 22.3% |
| Underlying ROE | 15.2% | 17.5% | 16.0% |
| FY24 to FY25 | HY25 to FY25 | |
|---|---|---|
| Opening Shareholders' equity | 49.9 | 45.5 |
| Change in Net OCI | 1.3 | 0.4 |
| Net income for the period | 9.8 | 5.9 |
| Dividend | -4.6 | - |
| Annual share buyback | -1.2 | - |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 | -3.5 |
| Undated subordinated debt (including interest charges) | -0.3 | -1.2 |
| Forex | -3.5 | -0.1 |
| Other | -0.6 | 0.3 |
| Closing Shareholders' equity | 47.2 | 47.2 |
Higher organic cash remittance and robust cash position at Holding
- In Euro billion
Net Cash Remittance
| FY24 | FY25 | |
|---|---|---|
| Proceeds related to in-force treaties2(footnote: €0.6bn proceeds related to L&S reinsurance in-force treaties at AXA France and AXA Life Europe.) | 0.6 | |
| Ordinary remittance | 7.1 | 7.5 |
| Total | 7.7 | 7.5 |
| Remittance ratio1(footnote: Based on ordinary cash remittance of Euro 7.1 billion in FY24 and Euro 7.5 billion in FY25.) | 82% | 82% |
| FY24 Cash position | 4.0 |
|---|---|
| Net cash remittance from subsidiaries | +7.5 |
| Dividend | -4.6 |
| Annual share buyback | -1.2 |
| Anti-dilutive share buyback following the sale of AXA IM | -3.5 |
| Holding costs and interest expenses | -1.3 |
| Change in net debt | +1.6 |
| M&A and other | +3.1 |
| FY25 Cash position | 5.6 |
Solvency II at 224%
- In Euro billion Foreseeable dividends: €-4.8bn Provision for annual share buyback for 2026: €-1.25bn
| FY24 | Regulatory & model changes | Normalized capital generation | Operating variance | Economic variance & FX | Dividend & annual share buyback | Management actions, debt & other | FY25 | |
|---|---|---|---|---|---|---|---|---|
| Eligible Own Funds (EOF) | 55.9 | +0.2 | +8.8 | -0.4 | -2.1 | -6.0 / -0.1 | 56.4 | |
| Solvency II ratio | 216% | +0pt | +28pts | -1pt | +4pts | -24pts | +2pts | 224% |
| Solvency Capital Requirement (SCR) | 25.9 | 0.0 | +0.6 | 0.0 | -1.2 | 0.0 | -0.2 | 25.2 |
Key sensitivities
- Ratio as of December 31, 2025: 224%
| Sensitivity | Impact |
|---|---|
| Interest rate +50bps | +2 pts |
| Interest rate -50bps | -1 pt |
| Corporate spreads +50bps | -1 pt |
| Euro Sovereign spreads +50bps1(footnote: Sensitivity to Euro sovereign spreads assumes a 50bps spread widening of the Euro sovereign bonds vs. the Euro swap curve (applied on sovereign and quasi-sovereign exposures).) | -7 pts |
| Credit migration2(footnote: Sensitivity to credit rating migration assumes 20% of corporate bonds (including private debt) held are downgraded by one full letter (3 notches).) | -4 pts |
| Listed Equity (excl. PE & Infra) +25% | -1 pt |
| Listed Equity (excl. PE & Infra) -25% | +2 pts |
| PE & Infra +25% | +14 pts |
| PE & Infra -25% | -19 pts |
| Inflation swap curve +50bps | -5 pts |
Solvency II – impact of the end of grandfathering period and Solvency II revision
- Ratio as of 31/12/2025: 224%
- Impact of the end of grandfathering period on January 1, 2026: -10pts to 215%
- Euro 2.4 billion grandfathered debt no longer eligible as capital from January 1, 2026
- Impact of Solvency II revision to come into effect in 1Q27: +17pts1(footnote: Estimated based on the Solvency Capital Requirement (SCR) and the amount of capital (EOF) under Solvency II as of January 1, 2026, as if the Solvency II revision had come into force on the same date.)
- No change expected in organic capital generation
- Additional capital flexibility
Conclusion
- Thomas Buberl, Group CEO
Conclusion
- Record results, at the top end of the target range while enhancing reserve prudence
- All businesses in excellent shape, delivering strong growth and profitability
- Diversified franchise, well-positioned to capture future growth opportunities
- Laying foundations for the next plan and confident in delivering sustainable earnings growth
Q&A
February 26, 2026
AXA Investor Relations – Keep in touch
Meet our management
- March | Roadshows | Europe and US
- May 5 | 1Q25 Activity Indicators | Paris
- June 2 | BNP Paribas Exane CEO Conference | Paris
- June 2-4 | Goldman Sachs European Financials Conference | Zurich
- July 31 | HY26 Earnings Release | Paris
- September 21 | AXA Investor Day | London
Contact us
- Investor Relations: +33 1 40 75 48 42 | investor.relations@axa.com
Follow us
- www.axa.com
Appendices
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
Gross financial debt and maturity breakdown as of December 31st, 2025
- In Euro billion
Gross financial debt1,2(footnote: 1. Nominal debt. 2. In January 2026, AXA has called (i) the remaining T2 GF £139m due 2054 callable 2034 5.625% issued January 2014 and (ii) the T1 GF €250m perpetual callable 2010 floating issued January 2005.) Contractual maturity breakdown
- Debt gearing 20.6% 22.3%
| FY24 | FY25 | Jan 1st 2026 | |
|---|---|---|---|
| Tier 1 | 4.8 | 4.6 | 3.2 |
| Tier 2 | 10.8 | 12.2 | 11.3 |
| Senior debt | 3.5 | 3.5 | 5.8 |
| Total | 19.2 | 20.3 | 20.3 |
- Jan 1st 2026: End of the grandfathering period
- o/w €0.4bn redeemed in Jan 2026
- Legend: Tier 1, Tier 2, Senior debt
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Senior debt | 0.9 | 1.5 | 0.5 | ||||||
| Tier 2 | 0.5 | 0.7 | 10.8 | 4.6 | |||||
| Tier 1 | 0.7 |
o/w Grandfathered debt (Contractual maturity breakdown)
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Tier 1 | - | - | - | - | - | - | - | - | 1.4 |
| Tier 2 | - | - | - | - | - | 0.7 | - | 0.2 | - |
Economic maturity breakdown3(footnote: 3. Economic maturity is taking into account the first date of step up calls on institutionally placed subordinated debt. For Solvency 2 RT1 debt, that has no step-up, the undated nature of the instrument is retained for the purpose of this diagram. This should not be construed, nor relied upon, as an indication that the instrument will not be called for redemption when callable. Such decision will depend on several factors, including our capital and liquidity position and the refinancing economics at the prevailing time.)
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Senior debt | 1.5 | 0.5 | |||||||
| Tier 2 | 0.1 | 2.4 | 0.5 | 2.0 | 0.4 | 6.4 | 0.7 | ||
| Tier 1 | 0.1 | 0.1 | 0.9 | 4.0 |
o/w Grandfathered debt (Economic maturity breakdown)
| 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031-2039 | ≥2040 | Undated | |
|---|---|---|---|---|---|---|---|---|---|
| Tier 1 | - | 0.1 | - | 0.1 | - | - | 0.4 | - | 0.8 |
| Tier 2 | - | - | - | - | - | 0.7 | 0.2 | - | - |
General Account Invested Assets
- FY25 Total General Account invested assets
- Duration gap at -0.4 year
| Fixed income | 77% |
| Real estate | 9% |
| Infrastructure equity | 2% |
| Listed equities | 2% |
| Private equity and hedge funds | 5% |
| Cash | 4% |
| Policy loans | 0% |
| FY25 | % | |
|---|---|---|
| Fixed income | 345 | 77% |
| o/w Government bonds | 167 | 37% |
| o/w Corporate bonds and loans | 121 | 27% |
| o/w Other fixed income 1(footnote: Other fixed income includes Asset Backed Securities (Euro 25 billion), Residential Loans (Euro 16 billion), Commercial & Agricultural Loans (Euro 7 billion) and Agency Pools (Euro 8 billion).) | 56 | 13% |
| Real estate | 41 | 9% |
| Infrastructure equity | 10 | 2% |
| Listed equities 2(footnote: Includes hedges. Listed equities excluding hedges at Euro 14 billion.) | 10 | 2% |
| Private equity and hedge funds 3(footnote: Includes Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).) | 23 | 5% |
| Cash | 19 | 4% |
| Policy loans | 2 | 0% |
| Total Insurance Invested Assets 4(footnote: Please refer to the financial supplement for more details.) | 450 | 100% |
Structured and Private Credit assets
| Invested assets (100%) In Euro billion |
FY25 | % of total G/A1(footnote: G/A: General Account) portfolio | Comments |
|---|---|---|---|
| Residential Mortgages | 16 | 4% | - €6bn Dutch mortgages, NHG guaranteed - €10bn self originated mortgages in Switzerland (56% LTV) and Germany (45% LTV) |
| CLO & ABS | 25 | 6% | - 91% senior CLOs with circa 40% subordination (100% rated AAA-A and 92% rated AAA-AA) |
| Infrastructure debt | 8 | 2% | - Skewed towards resilient industries (Telecom, Utilities, Transport) |
| CRE debt | 8 | 2% | - Strong sector diversification (mainly logistics, residential and retail), mostly in Europe, and circa 60% LTV |
| Mid-Market lending | 10 | 2% | - Strong diversification with €8m average ticket - Investments through SMAs with strict underwriting guidelines : senior secured, covenants, restrictions on asset sales and sector allocation |
| Other | 2 | 0% | |
| Total Structured and Private Credit Assets | 69 | 15% | o/w 54% participating |
Investment portfolio – Fixed Income reinvestment
FY25 Fixed Income Reinvestment
- Euro 57 billion
- Government bonds & related (32%) – Average rating: AA
- Investment grade credit (40%)- Average rating: A
- ABS/CLO/IG fund financing (21%)
- Below investment grade credit (7%)
FY25 Fixed Income Reinvestment Yield
| Public fixed income1(footnote: Government and Corporate bonds and related.) | Private & Structured fixed income2(footnote: Private & Structured credit (CLOs, ABS, Infra & CRE debt, Fund financing and Private hybrid).) | Total fixed income |
|---|---|---|
| 3.5% | 4.7% | 3.9% |
- Euro 57 billion fixed income invested at 3.9%
- Average duration of 9 years
- Includes Euro 19.7 billion of Private & Structured Credit invested at 4.7% (CLOs, ABS, Infra & CRE debt, Fund financing and Private HY)
- Gradual shift from alternative total return assets to Private & Structured credit
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
AXA XL Insurance – Large Commercial & Specialty business
Well diversified across lines of business and geographies
- $19bn FY25 GWP by line of business
- Casualty (35%)
- Property (29%)
- Specialty (19%)
- Professional lines1(footnote: Including Cyber) (17%)
- $19bn FY25 GWP by geography
- Americas (46%)
- Europe & APAC (35%)
- UK & Lloyds (19%)
Leading market positions across lines
- Top 3 globally
- Multinational Programs2(footnote: Source: McKinsey)
- Marine3(footnote: Source: Aon, Guy Carpenter, and Global Market Insights)
- Fine Art & Specie4(footnote: Source: Industry Research Biz (January 2026))
Managing the cycle to deliver consistent profitability
- Bubble chart with axes: Ex-price growth (%) (x-axis) and Profitability (y-axis); segments shown: Property (high profitability, high ex-price growth), Specialty, Casualty, Professional lines (lower profitability, lower ex-price growth)
P&C – Focus on Reserves
Claims reserves ratio
(Net undiscounted claims reserves/Net earned premiums)
| FY18 | FY19 | FY20 | FY21 | FY22 (IFRS4) | FY22 (IFRS17) | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|
| Claims reserves ratio | 179% | 185% | 193% | 188% | 189% | 198% | 195% | 180% | 175% |
Technical reserves ratio
(Net undiscounted technical reserves1(footnote: Includes net undiscounted claims reserves and unearned premium reserves.)/Net earned premiums)
| FY18 | FY19 | FY20 | FY21 | FY22 (IFRS4) | FY22 (IFRS17) | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|
| Technical reserves ratio | 213% | 227% | 233% | 226% | 227% | 234% | 232% | 216% | 210% |
P&C – 2026 Simplified Group Nat Cat Reinsurance Program1(footnote: Excludes local reinsurance covers;)
- In Euro
| EU Windstorm | Europe Flood | Europe Earthquake | NA Hurricane | NA Earthquake | Per other perils3(footnote: Other perils include Turkey earthquake, Other Europe and NA perils, South America Earthquake as well as a series of other secondary perils. Capacity varies by peril type.) | Reinsurance segment (illustrative) — Alternative Capital & Cat Bonds | |
|---|---|---|---|---|---|---|---|
| Capacity | 4.0bn | 2.1bn | 2.1bn | 1.2bn | 1.2bn | ||
| Retention | 600m | 450m | 400m | 600m2(footnote: Varying retention between MX and NA (400m MX, 600m NA);) | 600m2(footnote: Varying retention between MX and NA (400m MX, 600m NA);) | 400m |
- Stable retention levels maintained in 2026 as in 2025
P&C – AXA Group earnings deviation with different levels of Nat Cat cost1(footnote: Natural catastrophe cost defined as Aggregate Exceedance Probability (AEP) of all natural perils worldwide, net of tax and reinsurance. Deviation is compared to a normalized level, which are costs associated with natural catastrophes expected in an average year (ca. 4.5 points of estimated FY25 GEP, undiscounted and net of reinsurance). Full Year 2025 Earnings) in 2026
- In Euro billion (net of reinsurance)
Group underlying earnings deviation to average Nat Cat charges in 2026
- net of reinsurance, post-tax | net of reinsurance, pre-tax
| Scenario | Percentile | Deviation |
|---|---|---|
| 1/20y more severe | 95th | €-1.2bn |
| 1/10y more severe | 90th | €-0.8bn |
| 1/5y more severe | 80th | €-0.4bn |
| Median | 50th | €+0.1bn |
| 1/5y less severe | 20th | €+0.5bn |
| 1/10y less severe | 10th | €+0.7bn |
| 1/20y less severe | 5th | €+0.8bn |
- More severe years — Negative deviation in ca. 40% of cases
- Less severe years — Positive deviation in ca. 60% of cases
Average Expected Nat Cat charges
| 2025 | 2026 | |
|---|---|---|
| Amount (€bn) | 2.6 | 2.7 |
| Estimated impact on GEP | ca. 4.5% | ca. 4.5% |
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
P&C – Margin Analysis
#### Technical Result In Euro million (pre-tax)
| FY25 | Change | |
|---|---|---|
| Current Accident Year Undiscounted Technical Margin | 2,778 | +707 |
| Gross Earned Premiums | 57,656 | +6% |
| Current Accident Year Undiscounted Combined Ratio | 95.2% | -1.0pt |
| o/w Nat Cats | 3.4% | -0.4pt |
| FY25 | Change | |
|---|---|---|
| Current Accident Year Discounting | 2,009 | +115 |
| Discounting Ratio (in Combined Ratio points) | -3.5% | +0.0pt |
| Current Accident Year Net Claims reserves | €19.0bn | |
| Duration | 4.0 years | |
| Current Accident Year Discount rate | 2.8% |
| FY25 | Change | |
|---|---|---|
| Prior Years' Reserve Development (PYD) | 622 | -341 |
| PYD ratio | -1.1% | +0.7pt |
| +25bps | -25bps |
|---|---|
| €+0.2bn | €-0.2bn |
#### Financial Result In Euro million (pre-tax)
| FY25 | Change | |
|---|---|---|
| Investment Income | 3,988 | +435 |
| FY25 Average Assets | €115bn | |
| Asset book yield | 3.5% | |
| FY25 Reinvestment yield1(footnote: Reinvestment yield on fixed income assets.) | 4.3% |
| FY25 | Change | |
|---|---|---|
| Insurance Finance Expenses | -1,358 | -235 |
| FY24 Reserves at locked-in rate | €71bn | |
| Liability book yield | 1.9% |
| +25bps | -25bps |
|---|---|
| ~ €-50m | ~€+50m |
| FY25 | Change | |
|---|---|---|
| Underlying Earnings before tax | 8,040 | +681 |
| Tax | -2,060 | -169 |
| Affiliates, Minority interests & Other | -108 | -10 |
| Underlying Earnings | 5,872 | +501 |
| Growth vs. FY24 (at constant FX) | +9% |
L&H – Margin Analysis
- Includes scope impact
Technical Result
*In Euro million, pre-tax*
| FY25 | Change | |
|---|---|---|
| Short-term Technical Margin | 479 | +60 |
| Gross Earned Premiums | 17,416 | +10% |
| All Year Combined Ratio | 97.2% | -0.1pts |
- Incl. recapture of Laya
| FY25 | Change | |
|---|---|---|
| Long-term Technical Margin | 2,804 | +156 |
| CSM release | 2,954 | +215 |
| Technical experience | -150 | -58 |
| Baseline | 33.3 |
|---|---|
| Interest rates +50bps | -0.8 |
| Interest rates -50bps | 0.6 |
| Sovereign spreads +50bps | -1.9 |
| Sovereign spreads -50bps | 1.9 |
| Corporate spread +50bps | -0.8 |
| Corporate spread -50bps | 0.7 |
| Equities +25% | 1.8 |
| Equities -25% | -2.2 |
Financial Result
*In Euro million, pre-tax*
| FY25 | Change | |
|---|---|---|
| Investment Income (non-VFA only) | 2,484 | -1 |
| FY25 Average Assets | €98bn | |
| Asset book yield | 2.5% | |
| FY25 Reinvestment yield1(footnote: Reinvestment yield on fixed income assets.) | 3.8% |
| FY25 | Change | |
|---|---|---|
| Insurance Finance Expenses (non-VFA only) | -1,538 | -9 |
| FY24 Reserves at locked-in rate | €62bn | |
| Liability book yield | 2.5% |
| FY25 | Change | |
|---|---|---|
| Underlying Earnings before tax | 4,229 | +205 |
| Tax | -800 | 65 |
| Affiliates, Minority interests & Other | 72 | -51 |
| Underlying Earnings | 3,501 | +219 |
| Growth vs. FY24 (at constant FX) | +7% |
Contents
- 1. Debt and Invested Assets p.31
- 2. Additional P&C disclosures p.36
- 3. Additional IFRS17 disclosures p.41
Expanding AXA's role in society: AXA for Progress Index1(footnote: AXA's Sustainability Statement is subject to completion of a certification with limited assurance by AXA Group's auditors and will be presented to the AXA Board of Directors for approval on March 11, 2026.)
| As a GLOBAL INVESTOR | As a GLOBAL INSURER | As a COMPANY | |||
|---|---|---|---|---|---|
| Target | 2025 Result | Target | 2025 Result | Target | 2025 Result |
| €5bn2(footnote: Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.) in climate transition financing per year | €6.4bn | €6bn3(footnote: Scope: AXA France, AXA Germany, AXA Switzerland, AXA UK & Ireland, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Unit: Gross Written Premiums (GWP); Timeframe: cumulative 2024-2026.) in P&C GWP to support transition underwriting (cumulative 2024-2026) | €4.6bn | >80,0006(footnote: Number of employees who have been trained on climate change adaptation, completing a training under the AXA Sustainability Academy. Timeframe: cumulative 2024-2026.) AXA Group employees trained on climate adaptation by 2026 | 46,420 |
| >€500m2(footnote: Scope: corporate and sovereign debt, real estate and private assets. Timeframe: per annum through 2030.) in community resilience financing per year | >20,0004(footnote: Scope: Commercial lines portfolio of AXA France, AXA Germany, AXA Switzerland, AXA UK, AXA Belgium, AXA Hong Kong, AXA Mexico, and AXA XL; Climate solutions & services include (i) training/education, (ii) risk assessment/awareness, (iii) gap analysis, (iv) prevention/adaptation solution, and/or (v) crisis management/remediation response. Timeframe: cumulative 2024-2026. Following strong support within the Group for climate adaption solutions & services in 2024 and 2025, AXA is proposing a significant increase in its target for the 2024-2026 period, from >9,000 to >20,000.) climate adaptation solutions & services (cumulative 2024-2026) Target revised in 2025 | 19,698 Cumulative 2024-2025 | Contribute to Net-Zero -50%7(footnote: Variation of AXA Group absolute carbon emissions (scope: energy Scopes 1 and 2, car fleet and business travel). Timeframe: 2019-2030.) by 2030 in absolute carbon emissions and offset of residual emissions8(footnote: Carbon credits from projects that focus on capturing and storing carbon emissions from the atmosphere using nature-based or technical solutions (e.g. restorative agriculture, forest restoration or carbon capture and storage).) | -64% Reduction against 2019 | |
| €1.4bn | >20m5(footnote: Low-income to mass market segments in emerging markets and modest income segments in mature markets.) inclusive insurance customers by 2026 | 20.6m | 50% Percentage of AXA Group employees engaged in volunteering activities by 2026 | 56% | |
Sustainability Performance & Ratings
- S&P Global: 2025 percentile: 97th1(footnote: The CSA ranking is a key performance indicator for AXA Group, used to calculate the grant of Long-Term Incentives (more precisely AXA Restricted Shares). Results as of February 6th, 2026.) in Dow Jones Best-in-Class Europe & World indices
- MSCI: 2025 score: AAA
- CDP: 2025 score: B
- Morningstar Sustainalytics: 2025 ESG Risk Rating: 17.0– Low risk
- FTSE Russell: 2025 score: 4.3/5 in FTSE4Good Index Series
Scope
- France: includes insurance activities, banking activities and holding.
- Europe: includes Switzerland (insurance activities), Germany (insurance activities and holding), Belgium and Luxemburg (insurance activities and holding), United Kingdom and Ireland (insurance activities and holding), Spain (insurance activities and holdings), Italy (insurance activities), Prima (insurance activities) and AXA Life Europe (insurance activities).
- AXA XL: includes insurance and reinsurance activities and holding.
- Asia, Africa & EME-LATAM: includes (i) Asia: Japan (insurance activities and holding), Hong Kong (insurance activities), Thailand P&C, China P&C, South Korea, and Asia Holdings which are fully consolidated, and China L&S, Thailand L&S, the Philippines L&S and P&C, Indonesia L&S and India (Life activities disposed on March 11, 2024 and holding) businesses which are consolidated under the equity method and contribute only to NBV, PVEP, the underlying earnings and net income, (ii) Africa : Morocco (insurance activities and holding) and Nigeria (insurance activities and holding), Egypt (insurance activities and holding) which are fully consolidated, (iii) EME-LATAM: Mexico (insurance activities), Colombia (insurance activities), Brazil (insurance activities and holding) and Türkiye (insurance activities and holding) which are fully consolidated as well as Russia (Reso) (insurance activities) which consolidated under the equity method and contributes only to the net income, (iv) AXA Mediterranean Holdings.
- Transversal & Other: includes AXA Assistance, AXA Liabilities Managers, AXA and other Central Holdings.
- AXA Investment Managers (until July 1, 2025): includes AXA Investment Managers, Select (previously referred to as Architas) and Capza which are fully consolidated and Asian joint ventures which are consolidated under the equity method.
- Unless otherwise specified herein, all comparative figures for going back to 2023 are under the IFRS17/9 accounting standards that became effective on January 1, 2023. Figures for financial periods prior to 2023 have not been restated under IFRS17/9 and are presented under IFRS4, the applicable accounting standard that preceded the implementation of IFRS17/9
Glossary
- Capital-light G/A products: encompass all products with no guarantees, with guarantees at maturity only or with guarantees equal to or lower than 0%
- Contractual Service Margin (CSM): a component of the carrying amount of asset or liability for a group of insurance contracts representing the unearned profit to be recognized as services are provided to policyholders
- CSM release: a portion of CSM stock net of reinsurance at the end of the defined period flowing through profit and loss representing the estimated profit earned by the insurer for providing insurance services during the reporting period
- Economic variance: corresponds to the variance of the year-end CSM arising from changes in market conditions, net of the underlying return on in-force
- Financial result: consists of investment income on assets backing BBA and PAA contracts as well as assets backing shareholder’s equity, net of the insurance finance expenses (IFE) defined as the unwind of the present value of future cash flow
- Gross Written Premiums and Other Revenues (GWP & Other Revenues): represent the insurance premiums collected during the period (including risk premiums, premiums from pure investment contracts with no discretionary participating features, fees and revenues, net of commissions paid on assumed reinsurance business). Other Revenues represent premiums and fees collected on activities other than insurance (i.e. banking, services, and asset management activities)
- New Business Value (NBV): the value of newly issued contracts during the current year. It consists of the sum of (i) the new business contractual service margin, (ii) the present value of the future profits of short-term newly issued contracts during the period, carried by Life entities, considering expected renewals, (iii) the present value of the future profits of pure investment contracts accounted for under IFRS 9, net of (iv) the cost of reinsurance, (v) taxes and (vi) minority interests
- New Business Contractual Service Margin (NB CSM): a component of the carrying amount of the asset or liability for newly issued insurance contracts during the period, representing the unearned profit to be recognized as insurance contract services are provided
- New Business Value margin (NBV margin): ratio of (i) NBV, representing the value of newly issued contracts during the current year, to (ii) PVEP
- Operating variance: the variation of the year-end CSM versus the expected at opening due to (i) the differences between realized and expected operational assumptions, (ii) changes in assumptions such as mortality, longevity, lapses and expenses, and (iii) impact of model changes. Operating variance is net of reinsurance
- Present value of expected premiums (PVEP): the new business volume, equal to the present value at the time of issue of the total premiums expected to be received over the policy term. PVEP is discounted at the reference interest rate and PVEP is Group share
- Technical experience: consists the impacts on the underlying earnings if (i) the difference between the expected and incurred cash-flows of the defined period, (ii) the risk adjustment release, (iii) the changes in onerous contracts, and (iv) the other long-term elements which are mainly composed of non-attributable expenses
- Underlying return on in-force: represents the release of Time Value of Options & Guarantees (TVOG) plus the unwind of CSM at the reference rate plus the underlying financial over-performance